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Defining the Role of CtBP2 in p53-independent Tumor Suppressor Function of ARF 
 
ABSTRACT  
 
ARF, a potent tumor suppressor, positively regulates p53 by antagonizing 
MDM2, a negative regulator of p53, which in turn, results in either apoptosis or cell cycle 
arrest. ARF also suppresses the proliferation of cells lacking p53, and loss of ARF in 
p53-null mice, compared with ARF-null or p53-null mice, results in a broadened tumor 
spectrum and decreased tumor latency. This evidence suggests that ARF exerts both p53-
dependent and p53-independent tumor suppressor activity. However, the molecular 
pathway and mechanism of ARF’s p53-independent tumor suppressor activity is not 
understood.  
The antiapoptotic, metabolically regulated, transcriptional corepressor C-terminal 
binding protein 2 (CtBP2) has been identified as a specific target of ARF’s p53-
independent tumor suppression. CtBPs are phosphoproteins with PLDLS-binding motif 
and NADH-binding central dehydrogenase domains. ARF interacts with CtBP1 and 
CtBP2 both in vitro and in vivo, and induces their proteasome-mediated degradation, 
resulting in p53-independent apoptosis in colon cancer cells. ARF’s ability to target 
CtBP2 for degradation, and its induction of p53-independent apoptosis requires an intact 
interaction with CtBP2, and phosphorylation at S428 of CtBP2. As targets for inhibition 
by ARF, CtBPs are candidate oncogenes, and their expression is elevated in a majority of 
human colorectal adenocarcinomas specimens in comparison to normal adjacent tissue. 
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Relevant to its targeting by ARF, there is an inverse correlation between ARF and CtBP 
expression, and CtBP2 is completely absent in a subset of colorectal adenocarcinomas 
that retains high levels of ARF protein.    
CtBPs are activated under conditions of metabolic stress, such as hypoxia, and 
they repress epithelial and proapoptotic genes. BH3-only genes such as Bik, Bim and 
Bmf have been identified as mediators of ARF-induced, CtBP2-mediated p53-indpendent 
apoptosis. CtBP2 repressed BH3-only genes in a tissue specific manner through BKLF 
(Basic kruppel like factor)-binding elements. ARF regulation of BH3-only genes also 
required intact interaction with CtBP2. ARF antagonism of CtBP repression of Bik and 
other BH3-only genes may play a critical role in ARF-induced p53-independent 
apoptosis, and in turn, tumor suppression. 
To study the physiologic effect of ARF/CtBP2 interaction at the organismal level, 
the p19ArfL46D knock-in mice, in which the Arf/CtBP2 interaction was abrogated, was 
generated. Analysis of the primary cells derived from these mice, revealed that the 
Arf/CtBP2 interaction contributes to regulation of cell growth and cell migration. 
Overexpression of CtBP in human tumors, and ARF antagonism of CtBP repression of 
BH3-only gene expression and CtBP-mediated cell migration may therefore play a 
critical role in the p53-independent tumor suppressor function/s of ARF.  
 
  
Chapter-I  
 
Introduction 
 
1.1  Tumor Suppression 
 Cancer is a genetic disease in which abnormal cells divide without control and are 
able to invade other tissues. Cancer arises through a multistep process whereby cancer 
cells accumulate several genetic and epigenetic changes that eventually lead to the 
acquisition of malignant characteristics. The properties of neoplastic cells that distinguish 
them from cognate normal cells of the same tissue  have been categorized by Hanahan 
and Weinberg into six categories: 1) self sufficiency in growth signals, 2) insensitivity to 
growth-inhibitory signals, 3) evasion of apoptosis, 4) sustained angiogenesis, 5) invasion 
and metastasis and 6) capacity for sustained replicative potential 1. In addition to these six 
hallmarks, there are other characteristics of tumor cells, which include evasion of 
immune surveillance, and stress phenotypes, such as DNA damage/replication stress, 
proteotoxic stress, mitotic stress, metabolic stress and oxidative stress 2, 3. The mutations 
that may aid cancer cells in acquiring these capabilities occur in genes that encode a wide 
variety of proteins, often by modifying existing cellular programs normally used during 
development. The genes altered in cancer have been broadly categorized into two major 
classes: oncogenes and tumor suppressors.  
It has been suggested that cancers arise as a result of accumulation of somatic 
mutations in cellular protooncogenes 4. Deregulated (mutations in promoter, gene 
amplification, translocations or intragenic mutations) or abnormally overexpressed 
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protooncogenes govern several cellular processes such as cell proliferation, 
differentiation, and development. The mutations affecting these processes often 
constitutively deregulate specific signaling pathways. Studies involving somatic cell 
fusion and chromosome segregation have suggested that there are ‘antioncogenes’ which 
suppress tumorigenicity by opposing the effects of deregulated protooncogenes 5, 6.  
There are three cardinal properties of ‘classic’ tumor suppressor genes; first, they 
are recessive, requiring inactivation of both the alleles to induce tumor formation 7.  
Second, inheritance of a single mutant allele predisposes to tumor formation, as only one 
additional mutation is required for complete loss of function. Third, the same genes are 
frequently mutated in sporadic cancer 8. Tumor suppressor genes regulate a wide range of 
normal cellular functions. Although their predominant function is not to protect against 
cancer, their involvement in cell cycle check point control, cell senescence, DNA damage 
response, hypoxia, apoptosis and other signaling pathways demonstrates the gamut of 
cellular processes that can be deregulated during tumorigenesis and tumor progression.  
 
1.2  The INK4a/ARF locus 
 The INK4a/ARF locus on mouse chromosome 4 and the cognate locus CDKN2A 
on human chromosome band 9p21 both comprise four exons. The alternate reading 
frame tumor suppressor protein (ARF, also known as p14ARF in human and p19Arf in 
mouse) was identified as an alternative transcript of the INK4a locus 9. The structure of 
the INK4a/ARF locus is highly conserved among mammals 9, 10. By virtue of unique first 
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exons, the p16INK4a and ARF transcripts are translated in alternative reading frames and 
encode proteins with no amino acid homology (Figure 1.1).  
The INK4a gene encodes a polypeptide p16INK4a that inhibits cyclin D-dependent 
kinases CDK4 and CDK6 11. Further characterization of this locus revealed the presence 
of a similar INK4a gene, INK4b, which encodes a closely related kinase inhibitor 
p15INK4b (Figure 1.1). These kinase inhibitors exert their function by antagonizing the 
activities of G1 cyclin dependent kinases, which in turn prevents E2F-dependent 
transcription and cell proliferation 11.  The level of expression of p16INK4a and p19Arf is 
extremely low in most normal tissues. Therefore, these two proteins are not continuously 
restraining cell proliferation under physiological conditions, but rather, are activated in 
response to appropriate signals or additional stress. Oncogenes such as Ras, Myc, E1A 
and E2F1 differentially activate the expression of these proteins 12, 13, 14. Transcriptional 
activation of the INK4a/ARF locus results in cell cycle arrest or apoptosis. The ARF 
tumor suppressor protein antagonizes the functions of MDM2, a negative regulator of 
p53 and stabilizes p53 which results in p53-dependent cell cycle arrest and apoptosis 15. 
Not surprisingly, alterations in this locus affecting both p16INK4a and ARF are very 
common in human cancers 16. Three common modes of inactivation of this locus have 
been reported: (i) Homozygous deletion occurs in about 14% of all human tumors and 
often, it also involves the INK4b gene 17. (ii) Intragenic mutation accounts for 5% of 
tumors, especially point mutation in exon 2 that is shared by both genes. (iii) Promoter 
silencing by methylation, which results in complete inactivation of the two genes, has 
been found in about 19% of human tumors. Aberrant methylation of the ARF promoter 
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has also been found in human colorectal adenocarcinomas independently of INK4a 
promoter methylation 18. Tumors that retain a functional INK4a/ARF locus exhibit 
dramatic upregulation of its expression due to continued presence of oncogenic stress and 
other alterations accumulated during tumorigenesis. It has been reported that p16INK4a is 
accumulated in skin, bladder and lung carcinomas 19.  
The specific functions of ARF and INK4a in oncogenesis have been explored by 
targeted inactivation of the INK4a/ARF locus to generate whole animal and tissue-
specific tumor models 20. Mice deficient for both p16INK4a and p19Arf were generated by 
disruption of the shared exon 2 and 3 of the INK4a allele. Double-null mouse embryonic 
fibroblasts (MEFs) were able to overcome senescence at a faster rate compared to wild 
type MEFs and were highly susceptible to transformation with activated ras (H-rasVal12) 
21. Consistent with the fact that the INK4a/ARF locus encodes two tumor suppressors, 
69% of double-null mice developed spontaneous fibrosarcomas and lymphomas. Specific 
p19Arf-/- mice were then created by targeting exon1β, and about 80% developed various 
malignant tumors, including sarcomas and lymphomas within the first year 22, 23 (Table 
1.1). Additionally, p19Arf-/- MEFs demonstrated increased proliferation and susceptibility 
to H-ras mediated transformation 22, 23. In contrast MEFs derived from mice with exon 1α 
disruption, did not exhibit increased immortalization or susceptibility to H-ras mediated 
transformation as was observed in double-null or Arf-null MEFs 22, 24. However, 25% of 
p16Ink4a-/- mice did develop tumors, including soft tissue sarcomas,  
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Figure 1.1 The INK4b-ARF-INK4a locus.  
The locus consists of three tumor suppressor genes. Exons are indicated by letter E and 
colored rectangles and the promoters of the genes are designated by arrows. ARF is 
encoded by Exon1β, 2 and 3 with alternate reading frame in exon2. Both INK (INK4a 
and INK4b) genes encode inhibitors of cyclin D-dependent kinases CDK4 and CDK6 
(p16INK4a and p15INK4b respectively). Lower panel is schematic of p19Arf protein and 
amino acid sequence of Exon 1β encoded region. MDM2 binding (2-14 residues) and 
CtBP2 binding (37-51) and all conserved residues including L46D are indicated.  
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spleenic lymphomas and melanomas, though their incidence increases with mitogen 
treatment (Table 1.1) 24.  The majority of tumors in p53-null animals are lymphomas with 
a mean latency of 18-20 weeks, sarcomas being the second most common and 
carcinomas being rare 25, 26, 27. Arf-null mice develop similar type of tumors but with 
mean latency of 38 weeks verses 20 weeks in p53-null. ARF functions upstream of p53, 
hence Arf-null mice phenocopy p53-null mice, and the extended latency in Arf-null is 
explained by the fact that p53 is induced by cell stress, including genotoxic stress and 
oncogene activation whereas Arf is induced by only oncogenic stress. More than 70% of 
the tumors arising in p53-null mice are T-cell lymphomas (Table 1.1), whereas Arf-nulls 
had lower incidence of lymphomas but more sarcomas and carcinomas. This suggests 
that the increased latency in the Arf-null animals may lead to a shift in the tumor 
spectrum to include a wide variety of tumors, which tend to develop in older mice.  p53 
and Mdm2 double-null mice developed tumors with the same latency and tumor spectrum 
as p53-null, suggesting that Mdm2 functions through p53 by antagonizing it 28, 29. 
Interestingly, deletion of Arf in p53 and Mdm2 double-null mice results in a broader 
tumor spectrum with increased incidence of epithelial tumors, supporting the existence of 
an ARF tumor suppressor activity that functions independently of MDM2 and p53 30, 31.  
 
1.3 The ARF-MDM2-p53 pathway 
 The ARF tumor suppressor connects pathways regulated by canonical tumor 
suppressor proteins retinoblastoma (Rb) and p53. Inactivation of the Rb and p53 
pathways is very common in human cancers 16. Studies in murine and human cancers 
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suggested that these pathways are non-overlapping and their concomitant inactivation is 
cooperative during tumor progression. Upon sustained oncogenic stress such as 
overexpression of c-myc, v-abl, E2F or loss of Rb, ARF is transcriptionally induced 12, 13, 
32, 33, 34. Upon induction, ARF stabilizes p53 by antagonizing the E3 ligase activity of 
MDM2, sequestering MDM2 in the nucleolus, and by preventing MDM2-mediated 
nuclear export of p53 and subsequent degradation of p53 in the cytoplasm 35. 
Stabilization of p53 leads to activation of p53 transcriptional  target genes including 
MDM2, and results in either cell cycle arrest or apoptosis 36 (Figure 1.2). In the absence 
of p53, ARF levels are significantly elevated 10, however the reintroduction of wild type 
p53 into p53 null-cells can restore ARF levels to normal suggesting that there is a 
negative feedback regulation between ARF and p53 in vivo 37.  
 p19Arf expression in MEFs correlates with the onset of senescence and p19Arf-null 
cells do not senesce in culture 23, 38. However, p14ARF in normal human cells does not 
regulate replicative senescence 39, 40. Despite this difference, p14ARF does function as a 
tumor suppressor in humans as it is targeted for inactivation either by chromosomal 
deletion or transcriptional silencing by promoter methylation 16. ARF is frequently 
deleted in melanomas, biliary tumors, T- and B-cell ALLs, bladder, nasopharyngeal, and 
small cell lung carcinomas, and glioblastomas, strongly suggesting that ARF loss 
contributes significantly to human cancer 17, 41, 42. Often, ARF is inactivated in p53 
wildtype tumors as a putative alternative means of inactivating p53 function 41. In 
addition to inactivating MDM2, ARF can also enhance p53 function by inhibiting E3 
ligase activity of ARF-BP1/Mule, which directly interacts with and ubiquitinates p53 in 
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an MDM2-independent manner 43. Further, ARF increases the effectiveness of the p53 
pathway by promoting the phosphorylation and inhibition of transcriptional activity of 
the RelA subunit of NF-kB, which normally antagonizes p53 through induction of 
MDM2 and transcriptional repression of p53 44. 
 ARF is a very unusual protein with more than 20% arginine residues and 
isoelectric point greater than 12. Mouse p19Arf contains one lysine (K26) whereas human 
p14ARF has none. There are no recognizable structural motifs in ARF, but p14ARF can 
form stable oligomers upon exposure to oxidizing agents 45. Upon activation, ARF is 
localized to the nucleoli, an intranuclear organelle involved in ribosome biogenesis, and it 
forms high molecular weight complexes with nucleophosmin (NPM) 46, 47. NPM inhibits 
ARF turnover by sequestering it in the nucleoli and it regulates both ribosome biogenesis 
and in turn, the growth phase of the cell cycle.  
ARF stability and turnover are governed by N-terminal ubiquitination and 
proteasome-dependent degradation 48, 49. ARF has been reported to interact with more 
than 30 proteins,  some of which are implicated in p53-independent functions, however 
there is no evidence for ARF interaction with DNA or RNA directly 50.  Some of these 
ARF-interacting proteins are involved in ribosome biogenesis, transcriptional regulation, 
the DNA damage response, apoptosis and autophagy 50.   
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Figure 1.2 The ARF-MDM2-p53 pathway.  
Mitogenic signal acting through Ras stimulate phosphorylation of Rb, in turn interrupts 
its interaction with E2Fs and promote S phase entry. Upon oncogenic stress, ARF gets 
activated and interferes with the activity of MDM2, resulting in p53 stabilization. 
Activated p53 turns on the p53-dependent transcriptional program by regulating several 
target genes to induce either cell cycle arrest or apoptosis in a context dependent manner. 
In addition to directly activating p53, oncogenic stress can also activate protective DNA 
damage response. Depending on the signal, DNA-damage responses activate the kinases 
ATM or ATR and these kinases phosphorylate p53 directly or through CHK kinases and 
these phosphorylations activate transcriptional activity of p53 50, 51.  
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Table 1.1 Spontaneous and DMBA-induced tumor spectra of various genotypes of 
genes in ARF-MDM2-p53 pathway  
 
 
 
Genotype Spontaneous Tumors            % DMBA-induced                          % 
Wildtype Soft tissue Sarcomas  
Lung Carcinoma 
50 
50 
Small lymph. Lymphoma 
Soft tissue sarcoma 
Lung carcinoma 
69 
15 
15 
p16INK4a-/- Soft tissue sarcoma 
Osteosarcoma 
Histiocytic lymphoma 
Melanoma 
 
52 
18 
18 
12 
Small lymph. Lymphoma 
Soft tissue sarcoma 
Lung carcinoma 
Melanoma 
39 
35 
17 
9 
p19Arf-/- Small lymph. Lymphoma 
Soft tissue sarcoma 
Carcinomas 
Osteosarcoma 
 
37 
33 
20 
10 
Small lymph. Lymphoma 
Lung Carcinomas 
Soft tissue sarcoma 
 
60 
40 
15 
INK4a/ARF-/- Histiocytic lymphoma 
Soft tissue sarcoma 
 
90 
9 
Sarcomas 
Lymphoms 
60 
33 
p53-/- Lymphomas 
Sarcomas 
 
77 
23 
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1.4 p53-independent functions of ARF 
 Besides its canonical role in the p53-dependent tumor suppressor pathway, there 
also appear to be p53-independent functions of ARF. Simultaneous inactivation of p53 
and ARF in certain human tumors clearly suggests additional p53-indpendent tumor 
suppressor functions for ARF 52. Given the difficulty in distinguishing the tumor 
suppressor contributions of the often concordantly disrupted p16INK4a and ARF genes in 
humans 16, analysis of Arf knockout mice has provided additional evidence for p53-
independent functions of ARF. Epithelial tumors are rare in p53 knockout mice, however 
12%-28% Arf knockout mice developed epithelial tumors 23, 53. Further, combined loss of 
p53, Arf and/or Mdm2, results in a substantially increased incidence of epithelial cancers, 
including those of the digestive tract 30, 31. In fact, mice with loss of p53 and Mdm2 and 
retention of Arf display mainly mesenchymal tumors as in p53 knockout mice 31, 54. 
Additionally, in a transgenic K-ras skin cancer model, Arf loss accelerated tumor growth 
in a p53-independent manner 55.  
 At the cellular level, ARF can suppress the proliferation of p53-defective cells 31, 
56. There are two mechanisms by which ARF exerts this function.  Firstly, ARF binds and 
inactivates both c-myc and E2F proteins (Figure 1.3), thus slowing the cell cycle 
progression through the G1/S transition, and in turn, suppressing proliferation 57, 58. 
Secondly, ARF by localizing into nucleoli, forms a stoichiometric complex with 
nucleophosmin/B23, and disrupts ribosome biogenesis, and slows progression of cells 
through the growth phases of the cell cycle 47, 59, 60. smArf (short mitochondrial ARF) is 
translated from internal translational initiation site at methionine 48 in human and 45 in 
12 
 
 
 
mouse. smARF has been reported to induce autophagy by altering the mitochondrial 
membrane potential in p53-independent manner 61.  
 
ARF is not directly induced by DNA-damage signaling pathways, however ARF 
loss impairs the DNA-damage response indirectly, through its effects on Mdm2 and p53 
62. ARF is reported to activate both ATM and ATR and concomitantly, CHK1 and CHK2 
in cell lines lacking p53, in which the G1 checkpoint is defective, and upon p14ARF 
expression, cells arrested only in G2 phase 63. ARF activates ATM/ATR by interacting 
with and stabilizing TIP60, which in turn acetylates ATM 64. Upon DNA damage, the 
ARF/NPM complex gets disrupted and ARF is redistributed into the nucleoplasm and 
cytoplasm 65. However, the exact role of ARF in the DNA-damage response is not clearly 
understood. Most recently, mutagenesis studies with p14ARF revealed that the Val24 
residue is required for p53-independent growth suppression and multiple residues (Val24, 
Thr31, Ala41 and His60) facilitated ARF’s reversal of chromosomal instability in p53-null 
MEFs 66. It is suggested that ARF can promote chromosomal stability independent of p53 
through ATM which is a critical suppressor of chromosomal instability 67. 
  
  
  
13 
 
 
 
Figure 1.3 p53-independent Functions of ARF. ARF primarily functions as tumor 
suppressor by invariably inactivating its interacting proteins including MDM2 by 
sequestering them into nucleoli or altering their metabolic stability often inducing their 
degradation or by regulating their post-translational modifications such as sumoylation.  
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 To investigate the molecular mediators and mechanisms of the p53-independent 
functions of ARF and relate this activity to its tumor suppression, we have attempted to 
identify additional cellular targets of ARF. By use of yeast two-hybrid screen, the C-
terminal binding protein 2 (CtBP2) transcription regulator was identified as an ARF-
interacting protein. ARF interaction with CtBP2 induced degradation of CtBP2 by the 
proteasome 68. CtBP2 has been reported to function as antiapoptotic 69 and ARF-induces 
CtBP2 depletion resulted in apoptosis in a p53-independent manner suggested that CtBP2 
may function as mediator of ARF-induced p53-independent apoptosis, and in turn, p53-
independent tumor suppression by ARF. Though not yet proven, CtBP is likely to be 
linked to tumor progression, as it promotes both cell survival, cell migration and 
epithelial-mesenchymal transition by regulating proapoptotic and epithelial genes 
transcription 70. 
 
1.5 C-terminal Binding Proteins (CtBPs) 
 The C-terminal binding protein (CtBP) family proteins are unique in invertebrates 
and in vertebrates. The invertebrates have a single CtBP gene while vertebrates have two 
genes, CtBP1 and CtBP2. In humans, these map to chromosome bands 4p16 and 
10q26.13 respectively. CtPB1 and CtBP2 are expressed widely both during development 
and in adult tissue 71, 72. The vertebrate CtBPs have highly conserved sequence and 
structural similarity with D-isomer specific 2-hydroxy acid dehydrogenases (D2-HDH). 
CtBP1 was identified in 1993 as a 48 kDa cellular phosphoprotein that bound to the C-
terminal region of adenovirus E1A oncoprotein 73. CtBPs were shown to bind to a five 
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amino acid motif PLDLS conserved at the C-terminus of E1A by mutational analysis 74. 
CtBP2 protein was subsequently identified by EST sequence analysis and cloned by two 
hybrid screen against the transcription factor BKLF 75. CtBP1 localizes to both the 
nucleus and the cytoplasm, whereas CtBP2 localizes predominantly to the nucleus. This 
differential cellular localization of CtBPs is attributed to the difference in their N-
terminal 20 amino acids; CtBP2 has three N-terminal lysine residues which when 
acetylated by p300 confers nuclear localization on the protein 76.  
 
1.6  Cellular Functions of CtBP 
CtBP family members function in the nucleus as transcriptional corepressors by 
binding to a number of different DNA binding factors and modulating the expression of 
several genes that control development, oncogenesis, and apoptosis. In the cytosol, these 
proteins are involved in various functions associated with membrane trafficking, CNS 
synapse function and the regulation of microtubule cytoskeleton assembly 77, 78, 79.  
 
A. Nuclear Function of CtBPs  
i. Transcriptional Repression 
CtBPs function predominantly as transcriptional corepressors in the nucleus in 
conjunction with a number of different DNA-binding repressors. Initial studies with 
dCtBP in Drosophila embryos provided strong evidence for its role in transcriptional 
repression 80. Based on studies involving embryos deficient in maternal dCtBP and 
transgenic embryos containing repressors with CtBP-binding mutants, a number of 
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Drosophila repressors were identified which utilize dCtBP as a corepressor. The short 
range repressors such as Kruppel, Knirps, Snail, Giant and long range repressors such as 
Hairy and Groucho, require dCtBP for exerting their full repressor activity during 
embryonic development 80, 81, 82, 83.  
CtBPs contribute to transcriptional repression through sequence specific DNA-
binding core repressors, suggesting that CtBPs function as corepressors 84, 85.  So far, 
more than thirty different transcription factors have been suggested to exert their function 
through recruitment of  CtBP 86. In contrast, C. elegans homologue the ceCtBP can bind 
DNA directly through its N-terminal thanatos-associated protein (THAP) Zn2+ finger 
domain 87. Vertebrate CtBP associates with type I histone deacetylases (HDAC) 88, 89, 
though short range repressors functions normally in HDAC mutant embryos in 
Drosophila. CtBPs are reported to play a direct role in repression mediated by polycomb 
group (PcG) proteins such Pleiohomeotic (PHO) in Drosophila, and YY1 and HPC2 in 
mammals 90, 91, 92.   
Analysis of a tandem affinity tag purified (TAP) CtBP1 nuclear protein complex 
revealed that this complex is composed of a DNA-binding core repressor, CtBP and 
chromatin modifying factors.  CtBP recruits most of these factors through its PLDLS-
binding domain 93 (Figure 1.4). However, existence of such a high molecular mass 
complex suggests that there might be additional regulatory mechanisms and a very 
dynamic equilibrium in recognition of two PLDLS binding clefts of CtBP dimers (Figure 
1.4B).  In addition to the DNA-binding core repressors such as ZEB1/2, BKLF or 
Znf217, the CtBP complex contains the enzymes, which catalyze various modifications 
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on histones.  These include class I HDACs, histone methyl transferases (G9a and GLP), 
and lysine specific demethylases (LSD1). Components of the sumoylation enzyme 
machinery such as UBC9 (E2) and Hpc2 (sumo E3 ligase) are also part of the CtBP 
complex. Sumoylation of CtBP1 has been proposed to play a role in its nuclear retention. 
CtBP has been suggested to play a role in global repression by associating with 
bromodomain containing HAT coactivators (p300/CBP, GCN5) and basal transcription 
factors, including TAFIIF and TAFII-250 94, 95.  
 
ii. Transcriptional Activation 
Although CtBP family members primarily function as transcriptional corepressors 
by association with DNA-binding repressors, they may function as transcriptional 
activators under certain conditions. dCtBP function as a transcriptional activator in a 
context dependent manner in different mammalian cells when dCtBP was tethered with 
Gal4 96. Further, studies with CtBP2-null mouse embryos revealed that one of the target 
genes of Wnt3A, Brachyury was transcriptionally repressed compared to wildtype 
embryos.  In contrast to repression function, transcriptional activation seems to be an 
indirect effect. mTcf3 represses Brachyury through corepressor Gro, which contains two 
CtBP binding motifs.  It is possible that CtBP manifests its coactivator function by 
interfering with the repressor function of Gro. However, CtBPs may function as 
transcriptional coactivators in a cell specific, spatial and temporal-dependent manner.   
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Figure 1.4 Schematic representations of CtBPs domain structure and Model for 
transcriptional repression by CtBP.  
A. The physiologically relevant domains of CtBPs are PLDLS-binding motif, NADH 
binding dimerization domain which has the catalytic triad of D2-HDH activity. CtBPs 
nuclear localization is regulated by acetylation of K6, 8, 10 residues by p300. B. Model 
for gene specific transcriptional repressor function. CtBPs recruit core repressor and other 
factors associated with histone modification in to their PLDLS-binding clefts. Post-
translational modification such as phosphorylation and sumoylation may regulate the 
stability of this complex. Histone modifying factors include HDACs and HMTases, 
HATS and demethylases (LSD1).  
 
 
 
 
 
 
 
  
 
 
A 
B 
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B. Cytosolic Functions of CtBP 
 Although CtBPs predominantly function as transcriptional corepressors, splice 
variants of the vertebrate CtBP1 and CtBP2 have been suggested to function in various 
biological processes in the cytoplasm. The CtBP1 splice variant, BARS-50 was identified 
as a target for ribosylation by the fungal toxin brefeldin A (BFA) in the Golgi apparatus 
97. Ribosylation of BARS-50 is correlated with disassembly of Golgi by BFA. 
Reconstitution studies with wildtype and dominant negative CtBP/BARS confirmed that 
CtBP is important for the mitotic fragmentation of the Golgi complex 98. Further, CtBP1 
was shown to be involved in membrane fission and transport in dynamin-independent 
endocytic and exocytic transport pathways 99. However, there was no significant defects 
in Golgi apparatus partitioning in CtBP-null MEFs due to the possibility of compensatory 
mechanisms during embryonic development 72. RIBEYE, a variant of CtBP2, is a major 
component of the ribbon synaptic complex in the central nervous system and it is highly 
conserved across the species 77. CtBPs play both a structural role and a role in membrane 
turnover in the chemical synapse. Depletion of RIBEYE results in shorter synaptic 
ribbons. In addition to these cytosolic functions, the plant CtBP homolog AN also 
regulates microtubule cytoskeleton, and in turn, controls leaf shape by modulating the 
trichome (leaf hair) branching and polarized leaf cell expansion 78.  
 
1.7  Role of CtBPs in Development 
 CtBPs play an important role during development both in invertebrates and 
vertebrates. Homozygous deletion or inactivation of the dCtBP gene is lethal in 
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Drosophila 81. Progressive segmentation defects were observed with reduced levels of 
maternal dCtBP, which has been attributed to defects in the transcriptional repressor 
functions of short range repressors such as Hairy, Knirps, and Snail 81. Further, there is a 
link between dCtBP and the Wg (mammalian Wnt)  pathway during development 100. 
Studies conducted in Xenopus embryos have revealed that CtBPs play a critical role in 
development by regulating the transcriptional activities of Tcf-3, FOG and ZEB-1/SIP1 
101, 102, 103. A recent study of expression of CtBP1/2 in avian embryos suggests that these 
two genes may play functionally redundant roles in some tissues and unique roles in the 
development of others 104.  
Genetic analysis of mice with mutations in the CtBP1 and CtBP2 genes have 
suggested that the two CtBP isoforms have unique, as well as redundant, functions during 
mouse development 72. CtBP1-null mice are viable and fertile but are small and less 
robust, while homozygous inactivation of the CtBP2 locus results in embryonic lethality 
between E9 and E 10.5. The lethality in CtBP2-null mice was primarily due to vascular 
defects in the placenta, impairing the proper exchange of nutrients and waste. The 
phenotypic difference between CtBP1-/- and CtBP2-/- mice appears to be mainly due to 
differences in the tissue pattern of gene expression, as CtBP2 was the only CtBP 
expressed in placenta. Evidence for overlapping functions of CtBP1 and CtBP2 comes 
from genetic interaction studies between these genes by incorporating various 
combinations of CtBP1 and CtBP2 mutations. Embryos that are heterozygous for both 
genes are viable, however reducing the dosage of CtBP1 (CtBP1-/-/ CtBP2+/-) led to 
embryonic lethality with defects in vascular and skeletomuscular system development 72. 
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Some of the phenotypes associated with CtBP2 inactivation were attributed to a reduction 
in the expression of the T-box transcription factor Brachyury, which is a target of 
transcriptional coactivation by CtBPs.   
E1A expression in several cancer cell lines reverses their oncogenic properties, 
due to activation of various epithelial genes, and CtBP was identified as an antagonist of 
the epithelial phenotype 105. Indeed, a prominent phenotype associated with the deficiency 
of CtBP was the presence of extensive epithelial components in various tissues and 
organs. This is also consistent with the role of CtBP in repression of several genes 
important for conferring epithelial phenotype, such as E-cadherin 70. The signaling 
pathways controlled by CtBPs during development remain to be elucidated. However, 
several groups suggested that signaling pathways such as Wnt and TGF-β/BMP might 
play critical roles in concert with CtBPs during development. Mouse models with 
functional knock-in mutants of CtBPs would greatly facilitate to understanding of roles of 
CtBPs in vertebrate development.  
 
1.8  CtBPs in Oncogenesis and Apoptosis 
 The definitive role of CtBPs in oncogenesis is not clearly understood. Gene 
expression profiling of CtBP-null MEFs and CtBP rescued MEFs has also revealed that 
several epithelial (cytokeratins, tight junction components and lamins) and pro-apoptotic 
(such as Noxa, Bax and PERP) genes were activated in the absence of CtBPs 70. CtBPs 
interact with the APC (adenomatous polyposis coli) tumor suppressor and regulate the 
expression of intestinal retinol dehydrogenases, and in turn, the differentiation of 
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intestinal cells. CtBP appears to inhibit the wnt signaling pathway though it paradoxically 
activated wnt  100, 106. Adenomas from familial adenomatous polyposis patients showed 
high levels of CtBP protein in comparison to matching normal tissue. APC targets CtBP 
to proteasome-dependent degradation, however the mutated APC fails to do so, 
suggesting that CtBPs play an important role in colon adenoma formation. 
  
A. CtBP in Epithelial-Mesenchymal Transition, Cell migration and invasion 
 During the progression of epithelial tumors, crosstalk between the often 
heterogeneous tumor cells, the tumor stroma, and extra cellular matrix is essential. The 
Epithelial-Mesenchymal Transition (EMT), where cells undergo a developmental switch 
from a polarized, epithelial phenotype to a highly motile mesenchymal phenotype, has 
emerged as a key step during embryonic development, cancer progression, metastasis and 
chronic inflammation 107. Several signaling pathways including TGF-β, RTK/Ras, Wnt, 
Notch, Hedgehog and NF-kB are suggested to contribute to EMT.  Phenotypic markers of 
EMT include an increased capacity for migration and invasion, as well as resistance to 
anoikis/apoptosis. Indeed, CtBPs contribute to all of these characteristics of EMT 105, 108, 
109. Repression of E-cadherin by transcriptional regulators such as Slug, Snail, Zeb or 
Twist in various cellular contexts, emerged as one of the critical steps driving EMT. 
CtBP exerts its transcriptional corepressor function through these core repressors, 
suggesting that CtBP is important in promoting EMT. Zeb 1 overexpression with low 
levels of E-cadherin has been reported in several human cancers. In human colorectal 
adenocarcinomas, high levels of Zeb1 and CtBP were highly correlated with low levels of 
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E-cadherin 110. Studies from Dr. Grossman and Dr. Lewis lab have shown that CtBP2 
promotes cancer cell migration under hypoxic conditions in cells defective for p53 and 
introduction of ARF inhibits CtBP2-mediated cell migration 108, 109. Further, intact 
physical interaction of ARF/CtBP2 and NADH binding domain of CtBP2 were required 
for regulation of cancer cell migration 108, 109.  
Increased cellular NADH levels, such as in the hypoxic environment seen in solid 
tumors has been shown to enhance the recruitment of CtBP to the E-cadherin promoter 
111. Depletion of CtBP leads to reduced cell migration and invasion suggesting that the 
effect was independent of HIF-1α or other E-cadherin repressors  108, 109.  
 
B. CtBP transcriptionally represses several tumor suppressors 
 CtBPs play a significant role in repression of E-cadherin, which is involved in 
EMT as discussed above. E-cadherin limits tumor progression by restricting cell 
migration and invasion, in turn preventing tumor cells gaining malignant properties. 
Studies with CtBP knockout MEFs suggested that the PTEN tumor suppressor gene is 
also one of the CtBP transcriptional targets 70. The role of PTEN as a tumor suppressor 
has a direct link to its regulation of cell migration through the PI3K/Akt pathway. CtBP 
has also been suggested to play an important role in cell migration and invasion by 
targeting PTEN, and  in turn, the PI3K signaling pathway 108, 109 (Figure 1.4).  
Furthermore, recent studies have shown that CtBP transcriptionally regulate the Ink4 
family of tumor suppressors including p16INK4a and p15INK4b 112 (Figure 1.4). 
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C. CtBP as an Apoptosis Antagonist 
The initial evidence for an anti-apoptotic function of CtBP comes from studies 
involving expression of E1A mutants (CtBP-binding defective) which induce apoptosis in 
mammalian cells 105.Mouse embryonic fibroblasts from CtBP-null embryos are 
hypersensitive to apoptosis in response to a wide variety of stress signals, including loss 
of cell-cell contact (anoikis), Fas ligand and genotoxic agents 70.  Gene expression profile 
analysis of CtBP-null MEFs revealed the repression of several proapoptotic genes 
including PERP (p53-effector related to pmp-22), PTEN, insulin-like growth factor 
binding proteins, Bax, Noxa and Id-1 70. Further, siRNA-mediated depletion of CtBP in 
human tumor cell lines was sufficient to induce apoptosis without any additional stress 
113. CtBP also directly suppresses p53 target gene transcription such as Bax, through its 
interaction with Mdm2 and can thus regulate p53-dependent apoptosis 114. CtBPs are 
reported to associate with the Evi-1 repressor, which is a negative regulator of TGF-β 
signaling, and contributes to the progression of leukemias by inhibiting apoptosis 115.  In 
addition, CtBP also represses Id-1 expression by interacting with the inhibitory Smad, 
Smad6, which may contribute to an induction or suppression of apoptosis depending on 
the cellular context 103. 
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Figure 1.5  Role of CtBP in Oncogenesis and progression.   
The hypoxic environment during tumor progression, results in reduced NAD+/NADH 
ratio inside the cell, which stimulates the activity of CtBPs by increasing dimerization 
and affinity of binding with DNA binding repressors. CTBP has been suggested to 
enhance cell proliferation by repressing the cell cycle inhibitors p16INK4a and p15INK4b. 
Transcriptional repression of E-cadherin and PTEN results in promotion of Epithelial-
Mesenchymal Transition (EMT), cell migration and invasion. By repressing proapoptotic 
genes such as PERP, Bax and Noxa, CtBP promotes cell survival. CtBP being a potential 
oncogene, is targeted for degradation by several tumor suppressor proteins such as 
HipK2, APC, all of which directly associate with CtBPs 116. CtBPs also suppress 
transcription of p53 target genes through its interaction with Mdm2 114.  
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Post-translational modifications, such as phosphorylation, of CtBPs play a critical 
role in the induction of apoptosis after UV-irradiation. High doses of UV activate 
homeodomain interacting protein kinase 2 (HIPK2), which phosphorylates CtBP1 at 
serine 422 (conserved in CtBP2 at S428) and targets CtBP for ubiquitin-dependent 
degradation by the proteasome 69, 113. Other kinases may target CtBPs in cell-specific and 
context-dependent manner, and in turn, tighter regulation of CtBPs cellular functions.   
 
MEFs explanted from CtBP-null embryos were hypersensitive to apoptosis and 
microarray analysis has shown up regulation of proapoptotic genes such as PERP, PTEN, 
Bax, BH3-only gene; Noxa and Id1 70. It has been also suggested that CtBP depletion by 
specific siRNA in human cancer cells was sufficient to induce apoptosis without any 
additional stress 68.  To identify the mediators of ARF-induced p53-independent apoptosis 
mediated through CtBP, a human apoptosis array was performed with CtBP2 depletion 
either by ARF overexpression or by CtBP2 siRNA. BH3-only genes were identified as 
critical mediators of ARF/CtBP2 mediated p53-independent apoptosis.  
 
1.9 BH3-only proteins and Apoptosis 
 Programmed cell death or apoptosis is vital for the proper development and 
functioning of multicellular organisms. Tight regulation of apoptosis is essential for 
maintaining tissue homeostasis. The extent of tumor progression is determined not only 
by the rate of cell proliferation but also by the rate of cell death. Programmed cell death 
represents a major source of cell death as indicated from studies in mouse models, 
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cultured cells, and analysis of biopsied stages in human carcinogenesis. The acquired 
resistance towards apoptosis is a predominant trait of most, and perhaps all, types of 
cancers 1. Many of the proapoptotic signals converge on the mitochondria, which respond 
by releasing cytochrome C, a potent catalyst of apoptosis 117. Under several 
circumstances, a cell’s fate to live or die is largely governed by the Bcl-2 family of 
interacting proteins 118, 119.  The Bcl-2 family is comprised of pro-survival members (Bcl-
2, Bcl-xL, Bcl-w, Mcl-1 and A1) and two groups of pro-apoptotic members; Bax group 
(Bax, Bak, and Bok) with three BH (Bcl-2 homology) domains,  and the BH3-only 
proteins 118.  
 BH3-only proteins include Bim, Bid, Bad, Bik, Bmf, Puma, Hrk, and Noxa 
(Figure 1.5). Upon activation by cytotoxic signals, the BH3-only proteins interact with 
pro-survival members of the Bcl-2 family through their BH3 domain to prime apoptosis.  
In addition to BH3-only gene expression, subsequent activation of Bax or Bak is required 
for induction of apoptosis 120, 121.  Upon activation, BH3-only protein’s activate Bax or 
Bak by dissociating them from anti-apoptotic bcl-2 family proteins, and allowing them to 
translocate to the outer mitochondrial membrane to form pores that allow the cytoplasmic 
release of cytochrome C  122, 123.  Amongst BH3-only genes, Bid is a critical mediator of 
apoptosis mediated by death receptor signaling 124, Bim is the determinant of paclitaxel 
(Taxol), ionomyin and cytokine deprivation responsiveness 125, Puma and Noxa are 
central mediators of p53-induced apoptosis 126 and Bad regulates apoptosis mediated by 
growth factor/cytokine signaling 127. However, the cellular apoptotic stimuli that act 
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through Nbk/Bik, and the biologic functions of these genes in mammals, are not yet 
known, though they are induced upon proteasome inhibitor treatment of cells 128.  
The presence of multiple BH3-only proteins and their complex regulation allows 
for tight control of apoptosis in mammalian cells. Studies using knockout mice indicated 
that one or several BH3-only proteins play a dominant role in the induction of apoptosis 
in response to diverse cytotoxic and oncogenic stress stimuli (Figure 1.5).  To ensure 
proper tissue homeostasis by balancing cell death and cell proliferation, BH3-only 
proteins are restrained by multiple mechanisms  118, 119, 129. Bim, Puma, Hrk and Noxa are 
regulated transcriptionally, whereas Bad, Bik, Bmf, and Bik, are regulated by 
phosphorylation 130. BH3-only proteins exert their pro-apoptotic function by neutralizing 
pro-survival members of Bcl-2 family by associating with and sequestering them, or by 
directing them for proteasome-mediated degradation 131, 132.    
The BH3-only proteins play a very important role during tumorigenesis. Bcl-2 
and its homologues are very well recognized oncogenes 118. In contrast, their BH3-only 
antagonists function as tumor suppressors.  The apoptosis induced by DNA damage 
requires p53 and is critical for p53’s tumor suppressor function 133. Puma and Noxa are 
required for p53-dependent apoptosis 126. BH3-only protein deficient mice developed 
various types of neoplastic conditions such as leukemias and lymphomas in bim-null, 
renal carcinomas in bik-null mice, diffuse large B cell lymphoma in bad-null mice and 
CML in bid-null mice 134, 135, 136, 137. Other BH3-only proteins may likewise restrain 
oncogenesis in cell a specific manner. The development of peptide based or small 
molecule BH3 mimetics as novel targeted cancer therapeutics has been considered 118. 
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 Bik is a BH3-only endoplasmic reticulum associated phosphoprotein, with its 
BH3 domain and phosphorylation is required for its apoptotic function 138. Ectopic 
expression of Bik induces apoptosis in several mammalian cell lines and Bik interacts 
directly with Bcl-2 and Bcl-xL through its BH3 domain and inhibits their antiapoptotic 
functions resulting in the induction of apoptosis 139. Bik is normally expressed in 
hematopoietic component and endothelial cells 140. Bik is inducible by doxorubicin or γ-
irradiation in a p53-dependent manner 141, 142. Expression and activation upon certain 
apoptotic stimuli of Bik and Bim overlaps in the hematopoietic system, cardiomycocytes, 
and epithelial tissues of the kidney and mammary gland  140.  The bik and bim double-null 
mice studies indicated that both Bik and Bim share a critical role in spermatogenesis by 
regulating apoptosis, which is required for normal sperm development 143. In contrast, 
bik-null mice did not protect hematopoietic cells in vitro from apoptosis induced by 
cytotoxic stimuli or cytokine withdrawal, suggesting that the function of Bik in 
programmed cell death may overlap with that of other BH3-only proteins 140.  
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Figure 1.6 BH3-only proteins function in cellular homeostasis.  
Upon activation in response to a variety of cellular stresses, BH3-only proteins initiate 
apoptosis by interacting with and antagonizing Bcl-2 and Bcl-2 like pro-survival proteins 
via their BH3 domain (yellow triangle).  
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1.10 Aims of this Dissertation 
 ARF is silenced or deleted in a large number of human cancers. The role of ARF 
in tumor suppression has primarily been attributed to its role as a positive regulator of 
p53. However, multiple lines of evidence in mouse and human systems clearly suggest 
that ARF functions as a tumor suppressor apart from p53. The molecular pathways and 
mechanisms of this p53-independent tumor suppressor activity are not well understood. 
The transcriptional corepressor C-terminal Binding Protein (CtBP) has been identified as 
one of the interacting proteins involved in ARF-induced apoptosis in cells lacking p53. 
CtBPs are suggested to promote tumor progression by contributing to epithelial-
mesenchymal transition (EMT) and also function as apoptosis antagonists. These findings 
have indicated that CtBPs are candidate oncogenes, and that they are targeted by tumor 
suppressors. Therefore, the main aims of this dissertation are to delineate the functional 
significance of the ARF/CtBP2 interaction, to determine the mechanism of ARF-induced 
p53-independent apoptosis, and to investigate the biological significance of the 
ARF/CtBP2 interaction in vivo by generating and characterizing a knock-in mouse 
containing a targeted mutation of the CtBP-interacting domain of Arf.  A deeper 
understanding of the ARF/CtBP pathway in murine and human systems could allow 
development of targeted therapeutics that aim to restore the function of this pathway that 
might be lost in tumors that silence or delete ARF.                                                                                                                                                               
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Chapter-II 
 
ARF-induced CtBP2 degradation is part of a p53-independent tumor suppressor 
pathway targeted for inactivation in human cancer 
Abstract 
ARF, a potent tumor suppressor, stabilizes p53 by antagonizing its negative 
regulator MDM2. ARF also suppresses the proliferation of cells lacking p53, and loss of 
ARF in p53-null mice, compared with ARF-null or p53-null mice, results in a broadened 
tumor spectrum with decreased tumor latency. The transcriptional corepressor C-terminal 
binding protein 2 (CtBP2) has been identified as a putative target of p53-independent 
tumor suppression by ARF. ARF interacted with CtBP2 in vitro and in vivo. Interaction 
with ARF resulted in proteasome-dependent CtBP degradation, and required 
phosphorylation at serine 428. ARF-induced CtBP depletion led to p53-independent 
apoptosis in human colon cancer cells. Both ARF induced CtBP degradation and 
induction of apoptosis was dependent on its ability to interact with CtBP. As a target for 
inhibition by ARF, CtBP is a candidate oncogene, and its expression was deregulated in 
human colonic adenocarcinomas. CtBP expression level was elevated in more than 65% 
human colorectal adenocarcinomas tissue samples compared to their matching normal 
tissue. Moreover, CtBP expression was absent/decreased at the protein level in 25% of 
colorectal adenocarcinomas, and these tumors specifically expressed high levels of ARF. 
Overexpression of CtBP in human tumors may be selected for in oncogenesis to both 
overcome ARF-dependent degradation and inactivate other functions of ARF.  
34 
 
 
 
Introduction 
ARF (mArf in mouse and hARF in human), a tumor suppressor product of the 
INK4a/ARF locus, functions by stabilizing p53 36, 144, 145, 146, 147.  Given the fact that ARF 
stabilizes and activates p53 by antagonizing MDM2, inactivation of ARF has been 
attributed to inactivating the p53 pathway during tumorigenesis 23, 148. The INK4a/ARF 
locus is frequently inactivated in human cancers by deletion or transcriptional silencing 
or mutation 16. Arf knockout mice developed highly penetrant lymphomas or sarcomas, 
similar to the types of tumors observed in p53-deficient mice 23, 53. The finding that 
simultaneous inactivation of p53 and INK4a/ARF occurs in certain human tumors, 
however, suggests that ARF may exert additional tumor suppressor function(s) 
independent of p53 52. 
The p16INK4a and ARF genes are often simultaneously deleted in humans, thus it 
is difficult to distinguish their contributions to tumor suppression 149, 150. However, 
analysis of ARF-specific knockout mice has provided additional evidence for p53-
independent functions of ARF.  Epithelial tumors are rare in p53-null mice, but observed 
in about 20% of Arf knockout mice, and simultaneous targeting of both Arf and p53 
results in an even higher frequency of epithelial tumors 53, 151, 152. Further loss of MDM2, 
a negative regulator of p53, results in a substantially increased incidence of epithelial 
cancers, including those of the digestive tract 30, 31. In contrast, mice with loss of p53 and 
MDM2, but retention of Arf, developed only mesenchymal tumors, as observed in p53 
knockout mice 31.  This genetic evidence in mice also suggested that ARF exerts a tumor 
suppressor activity apart from stabilizing p53. 
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Studies in cell lines also revealed that ARF can suppress the proliferation of p53-
defective cells 31, 147. ARF executes this function by antagonizing c-myc and E2F (E2F1-
3), accelerating their degradation via the proteasome, thus slowing progression of cells 
through the G1/S transition and decreasing proliferative rate  153, 154. ARF can also disrupt 
ribosome biogenesis by interacting with nucleophosmin/B23 and/or by interfering with 
the export of ribosomal RNA 46, 47, 59, 60, 155.  This, in turn, would inhibit cell proliferation 
by retarding the progression of cells through the growth phases of the cell cycle.  
ARF affects the function of its interacting proteins by sequestering them into 
nucleoli, targeting them for degradation, or affecting their state of post-translational 
modification 148. E2Fs, c-myc, and MDM2 are sequestered into the nucleoli upon ARF 
expression 31, 57, 148, 156. Other targets display changes in their post-translational 
modifications or localization: MDM2 and B23 become sumoylated 157, 158.   109, 159 
In an attempt to understand the p53-independent functions of ARF and relate this 
function to tumor suppression, a two-hybrid screen of ARF interactors was performed, 
identifying C-terminal binding protein 2 (CtBP2) transcription regulator as an ARF-
binding protein. ARF interaction caused proteasome-mediated CtBP degradation, 
dependent on CtBP phosphorylation. Depletion of CtBP either by ARF expression or by 
RNAi resulted in apoptosis in a p53-independent manner in human colon cancer cells that 
was dependent on ARF/CtBP interaction. Importantly, an inverse correlation between 
ARF and CtBP expression observed in human colorectal adenocarcinomas, validating 
results gained in biochemical and cell line studies.  
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Results 
ARF and CtBP interact in vitro and in vivo 
A yeast two-hybrid assay was employed in an attempt to identify the mediators of 
ARF’s p53-independent functions. CtBP2 was thus identified as an ARF interacting 
protein. To characterize the putative ARF/CtBP interaction, purified GST or GST-mArf 
fusion proteins were incubated with U2OS cell lysates.  GST-mArf, but not GST, was 
able to specifically recognize the endogenous 48 kDa CtBP2 protein from U2OS cell 
lysates, suggesting that these proteins can specifically interact in vitro (Figure 2.1A). To 
map the binding of mArf to CtBP2, V5-tagged N-terminus (1-321) and C-terminus (322-
445) constructs of CtBP2 were transiently expressed in U2OS cells followed by analysis 
for binding of the V5-CtBP2 proteins to purified GST vs. GST-mArf. The C-terminal 
fragment (322-445aa), but not the N-terminal fragment of hCtBP2 (1-321aa), bound 
specifically to mArf (Figure 2.1A).   
To determine the minimal region of mArf required for CtBP interaction, wild type mArf 
or deletion mutant mArf expression constructs were expressed along with CtBP2 in 
U2OS cells and immunoprecipitated with CtBP2 antibody. Wildtype mArf, and its 
mutants defective for Mdm2 binding (∆8-32), or nucleolar localization (∆26-37), all 
coimmunoprecipitated with CtBP2 (Figure 2.1B). However, the mArf mutants of a 
conserved but uncharacterized domain (L46D, ∆32-51, and ∆46-51) did not 
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coimmunoprecipitate with CtBP (Figure 2.1B). Thus, mArf residues between 37 and 51 
were required for hCtBP2 interaction  
To determine if ARF/CtBP interaction could be observed in human cells, U2OS 
cells were transfected with hCtBP2 and full-length hARF or hARFL50D (homologous to 
mArfL46D) expression vectors, and the transfected cell lysates were immunoprecipitated 
with anti-CtBP2 or a control IgG antibodies, followed by immunoblotting with CtBP2 
and ARF antibodies.  ARF but not the hARFL50D mutant was evident in the anti-CtBP2 
IP, which was consistent with mArf/CtBP interaction (Figure 2.1C).   
 
p19ArfL46D and p14ARFL50D CtBP-binding defective mutants retain p53-dependent 
functions and nucleolar localization of ARF 
 By biochemical interaction assays, the minimal region of ARF required for CtBP2 
interaction was localized within residues 37-51. This domain is highly conserved across 
the species (Figure 1.1) but uncharacterized for any functional significance. To determine 
whether this region contributes to p53-dependent functions, the CtBP interaction 
defective (L46D/L50D) ARF mutants and the MDM2-binding defective mutant 
constructs were transfected into U2OS cells along with p53-HA and MDM2 (Figure 
2.1B). Loss of residues 46-53 or the L46D point had little or no effect on Arf-induced 
p53 stabilization in U2OS cells (Figure 2.2A) or Arf induced G1 cell cycle arrest (a p53-
dependent function) in MEFs (Figure 2.2B). Consistent with previous reports, the MDM2 
binding-defective Arf mutant ∆8-32 failed to stabilize p53 or induce cell cycle arrest 
(Figure 2.2A-B). Similarly, the hARFL50D mutant also retained its p53 stabilization 
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function when expressed in either U2OS or HCT116 cells (Figure 2.2D-E). Further, both 
the mArfL46D and hARFL50D mutants exhibited nucleolar localization similar to wildtype 
ARF (Figure 2.2C and F). These data suggest that disruption of the CtBP-binding domain 
of ARF does not disrupt its ability to interact with and antagonize MDM2, and in turn, 
stabilize and activate p53.   
 
ARF induces CtBP degradation 
ARF-interacting proteins can show major alterations in their metabolic stability.  
MDM2 is stabilized, whereas MDM-x, E2F1-3, and B23/nucleophosmin are destabilized 
when complexed with the ARF/MDM2 complex or ARF alone 127, 153, 160.  CtBP is 
degraded by the proteasome after UV exposure, resulting in induction of apoptosis 113.  
Interestingly, the human cancer cell lines in which CtBP degradation was observed after 
UV, invariably expressed ARF  113, suggesting that a potential function of the ARF/CtBP 
interaction is to induce CtBP degradation.  
To confirm the requirement of ARF for CtBP degradation, mArf wild-type (wt) or 
mutant alleles were introduced into ARF-negative U2OS cells (Figure 2.3A, E).  
Expression of Arf sensitized U2OS cells to UV-induced loss of hCtBP2 (Figure 2.3A-B). 
Consistent with a role of ARF interaction in directing CtBP degradation, expression of 
mArf mutants defective for hCtBP2 interaction (L46D, Δ46-51) did not induce hCtBP2 
loss in UV-treated cells, whereas wt mArf or mArf(Δ8-32), which is defective for MDM2 
interaction and nucleolar localization, were capable of targeting hCtBP2 for degradation 
after a UV dose of 10J/m2 (Figure 2.3A-B). Thus, the ability of ARF to form a 
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biochemical complex with CtBP2 correlated with its ability to direct CtBP2 degradation. 
ARF-induced CtBP2 degradation was blocked by a proteasome inhibitor (Figure 2.3E), 
which is consistent with a previous report that proteasome inhibition blocked UV-
induced degradation of CtBP1 69.  
To confirm that human and mouse ARF have similar effects on CtBP metabolism, 
hARF was introduced into HCT116 colon cancer cells wt or null for p53 using a 
recombinant adenovirus 161, 162. Surprisingly, hARF expression alone, without any 
additional stresses such as UV, resulted in a loss of hCtBP2 not seen in cells infected 
with a control virus, and irrespective of p53 status (Figure 2.3C). To rule out the 
possibility that ARF’s effect on CtBP was transcriptional, a semi-quantitative RT-PCR 
was performed with CtBP2 primers on RNA isolated from control or ARF virus infected 
HCT116; p53-/- cells. Though there was a decrease in abundance of CtBP2 protein in 
ARF expressing cells, there was no significant change in CtBP mRNA levels, suggesting 
that the effect of ARF on CtBP2 protein level was posttranscriptional (Figure 2.3D). 
 
To rule out the possibility of influence of viral infection of CtBP2 loss upon Ad-
ARF transduction, hARF and L50D mutant expression constructs were transfected into 
HCT116; p53-/- cells. ARF was competent to cause CtBP depletion upon transfection, 
but the L50D mutant of hARF failed to do so, though it was expressed at similar levels. 
This clearly suggested that the intact interaction of ARF/CtBP2 is required for CtBP2 
degradation (Figure 2.3F).  
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ARF induced CtBP2 degradation requires phosphorylation at serine 428.  
UV-induced degradation of CtBP and ARF-induced degradation of CtBP 
presumably share a common mechanism based on the ARF requirement for UV-induced 
CtBP degradation 68.  HIPK2 or JNK1 phosphorylation of CtBP1 at S422 is required for 
UV-induced CtBP1 degradation 68, suggesting that CtBP phosphorylation is also required 
for non-stress ARF-induced degradation 68, 69, 163. To answer this question, CtBP2 residue 
S428, paralogous to the S422 HIPK2 site in CtBP1, was mutated to alanine, which 
prevents phosphorylation when expressed in vivo. When ARF was cotransfected with 
CtBP2-V5 and CtBP2V5-S428A, there was a significant reduction in the levels of wt 
CtBP2-V5, whereas CtBP2-S428A was not affected by ARF coexpression (Figure 2.4A). 
This supports the requirement of S428 phosphorylation for ARF-induced degradation of 
CtBP2.  
 To rule out the possibility that ARF does not affect CtBP2-S428A due to a defect 
in ARF/CtBP2 interaction, these two proteins were assayed for binding in a 
coimmunoprecipitation assay. Lysates of U2OS cells transfected with ARF, CtBP2 or 
CtBP2-S428A constructs were used for immunoprecipitation using control IgG, anti-
CtBP2 and anti-ARF antibodies. ARF showed similar avidities for both the wt CtBP2 and 
the CtBP2-S428A mutant (Figure 2.4B), suggesting that the resistance of CtBP2-S428A 
mutant to ARF-induced degradation was not due to loss of interaction between ARF and 
the mutant CtBP2.  
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CtBP depletion by ARF is sufficient to trigger p53-independent apoptosis  
To determine whether ARF-induced CtBP depletion could be linked to its tumor 
suppression function, wild type or p53-null HCT116 cells were transduced with Ad-
hARF or control Ad-lacZ virus and assayed for apoptosis.  Both of the cell lines 
demonstrated a significant activation of the apoptotic marker caspase 3 (20-23 % of cells) 
after Ad-hARF infection regardless of p53 status (Figure 2.5A). To correlate ARF/CtBP 
interaction with ARF-induction of p53-indepdendent apoptosis, wt ARF and hARFL50D 
were compared for their ability to induce apoptosis. HCT116; p53-/- cells were infected 
with empty (Ev), ARF or L50D retroviruses, and analyzed for apoptosis induction by 
Annexin V-PE/7-AAD staining (Figure 2.5B). As expected, hARF expressing cells 
exhibited increased annexin V positivity (20%), whereas hARFL50D expressing cells 
exhibited annexin V positivity similar to that of empty vector control (11% versus 10%) 
(Figure 2.5B).  Therefore, the ability of ARF to interact with and degrade CtBP correlates 
with its ability to induce p53-independent apoptosis.  
 
CtBP and ARF levels vary coordinately in human colon tumors 
ARF expression is lost by methylation in ~22-38% of colon cancers, suggesting 
that the remaining colon tumors express ARF to varying degrees, with the majority of 
ARF-expressing tumors likely to have disruption of p53 164, 165.  One could imagine that 
high-level ARF expression, if detrimental to growth and progression of a cancer, even 
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after p53 loss, might be counteracted by other means than transcriptional silencing, such 
as overexpression or mutation of p53-independent targets like CtBP.  Though by in vitro 
assay CtBP generally displays pro-oncogenic properties, it has never been proven to 
represent a cellular proto-oncogene. To test the idea that CtBP is targeted by ARF for 
inhibition during in vivo epithelial tumorigenesis, a series of 70 resected primary colon 
tumors with corresponding adjacent normal tissue were analyzed for CtBP1/2, hARF, and 
GAPDH protein levels by immunoblot (Figure 2.6A) and CtBP2 and GAPDH mRNA 
levels by RT-PCR (Figure 2.6B).   
Three CtBP and ARF expression patterns were observed (Figure 2.6A; Class I-III; 
summarized in table). The majority of the tumors (65%) expressed substantially higher 
levels of CtBP1/2 than adjacent normal tissue, and ARF was undetectable in both normal 
and tumor tissue. However, 25 % of tumors demonstrated a striking absence of CtBP1/2 
and specifically expressed high levels of ARF. Notably, the matched normal samples for 
Class II tumors invariably contained high levels of CtBP1/2 protein, as seen in matched 
normal samples from Class III tissues, but unlike the matched normal class I specimens. 
The inverse correlation between ARF and CtBP was significant with p<0.00001, when 
the Chi-square test was applied. RT-PCR analysis of these tissue samples for CtBP2 
mRNA showed no significant difference between normal and tumor specimens where 
protein levels were disparate (Class I and Class II) (Figure 2.6B), suggesting that the loss 
of CtBP2 expression in tumors was post-transcriptional, possibly due to ARF-induced 
degradation. Thus, analysis of a series of colorectal cancer resection specimens suggested 
that majority of these tumors (Class I and II) demonstrate an inverse relationship between 
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ARF and CtBP (1 and 2) protein expression, which is consistent with findings from our 
cell line based studies.  
 
Discussion 
ARF functions as a tumor suppressor by p53-dependent and p53-independent 
mechanisms 10, 31, 148. However, the molecular mechanism underlying the p53-
independent tumor suppressor function/s of ARF remains unclear. Previous studies have 
shown that ARF can induce growth arrest or apoptosis in cells lacking p53 in a context 
dependent manner 31, 166. In this study, we have identified CtBP2, a metabolically 
sensitive transcriptional corepressor, as a target for the p53-independent functions of 
ARF. ARF induced proteasome-mediated CtBP2 degradation, and in turn, efficient 
apoptosis in human colon cancer cells lacking p53.  Both ARF-dependent CtBP2 
degradation and the induction of apoptosis correlated with the ability of ARF to interact 
with CtBP. ARF-induced CtBP2 degradation also required the phosphorylation of CtBP2 
at S428. Further, an inverse correlation between CtBPs and ARF protein expression 
levels was observed in human colorectal adenocarcinomas.  
A conserved hydrophobic domain (37-51 residues) in exon 1β of ARF recognized 
the C-terminus of CtBP. The point mutation in this conserved hydrophobic region of 
ARF (L46D in mArf and L50D in hARF) abolished ARF/CtBP interaction, and in turn, 
ARF-induced p53-independent apoptosis. However, both mArfL46D and hARFL50D did 
not affect p53-dependent functions of Arf, suggesting that this domain is distinct from the 
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MDM2 binding region, and may not contribute to p53-dependent functions of ARF in 
vivo.   
Upon UV irradiation, CtBP1 gets ubiquitinated and this is dependent on S422 
phosphorylation (S428 in CtBP2) by HIPK2 kinase. Our data also suggest that hARF-
induced CtBP degradation requires phosphorylation at S428 but this phosphorylation was 
not required for ARF/CtBP2 interaction, suggesting that S428 phosphorylation may 
regulate UV-induced or ARF-induced CtBP degradation at a step beyond the ability of 
CtBP and ARF to interact. That step could be a delivery of ubiquitinated substrates to the 
proteasome and CtBP2 phosphorylation at S428 may aid in this process. Further, our 
preliminary data suggests that ARF may function as a proteasome adaptor by physically 
associating with the S6a subunit of the 19s regulatory assembly of proteasome (Appendix 
I, Fig A1.1) 167 or may aid in recruiting other proteasome adaptors such as hPLIC and 
Rad23 proteins to ensure efficient degradation of ubiquitinated substrates 168. hARF had a 
much more robust destabilizing effect on CtBP than mArf, which required additional UV 
stress to induce CtBP degradation. Though the CtBP binding region in ARF is well 
conserved across the species, the minor sequence differences between human and mouse 
ARF might contribute to their difference in causing CtBP degradation.  
ARF expression in human colon cancer cells lacking p53 induced CtBP 
degradation, and in turn, efficient apoptosis. However, apoptosis has also been observed 
after CtBP depletion using specific siRNA alone 68. This clearly suggests that ARF 
functions upstream of CtBP in this pathway. Repletion of CtBP in ARF expressing cells 
by exogenous expression has rescued cells from ARF-induced apoptosis, confirming a 
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direct role for CtBP in the apoptosis pathway activated by ARF in the absence of p53 68. 
Our results and previously reported work suggest that CtBP functions as antiapoptotic 
protein through repression of proapoptotic gene expression 113. Targeting of CtBP by 
ARF may result in abrogation of this transcriptional repression, and in turn, induction of 
apoptosis. The proapoptotic genes regulated by CtBP2 may function as the mediators of 
ARF-induced p53-independent apoptosis.  
ARF is a frequent target for silencing in a variety of human carcinomas including 
human colorectal adenocarcinomas 55, 164, 169, 170. The tumor suppressor function of ARF 
has also been confirmed by Arf knockout mouse models 23, 152. The molecular 
mechanisms by which ARF proteins suppress tumors remain unclear, and may depend on 
specific cellular and tissue contexts.  Both hARF and mArf are associated with p53-
dependent functions such as growth arrest, senescence and apoptosis, predominantly due 
to stabilization of p53 10, 171.  These functions are critical for suppression of certain 
hematopoietic malignancies, such mouse Eµ-Myc transgene-driven B cell lymphomas, 
and likely human T-ALL 172, 173, 174, 175.  However, suppression of epithelial tumors in 
mice by ARF is at least partly p53-independent, and the underlying mechanism is 
unknown 55. Our data from human colorectal adenocarcinomas showed an inverse 
correlation between ARF and CtBP expression levels. The majority of human colorectal 
adenocarcinomas displayed elevated levels of CtBPs with no detectable ARF, supporting 
the contention that CtBP may function as a cellular proto-oncogene. Interestingly, class II 
tumors displayed a striking absence of CtBP expression with retention of ARF 
expression. Thus, this group of tumors may harbor additional changes such as mutations 
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in PI3 kinase or upregulation of core repressors of CtBP or other changes, to enable these 
tumors to sustain the complete loss of CtBPs and continued presence of the ARF tumor 
suppressor. Normal specimens from class II and III invariably displayed high levels of 
CtBPs which may be due to the existence of precancerous but morphologically silent 
changes adjacent to tumors or specific differences in CtBP expression patterns in those 
groups of patients. Further study of truly ‘normal’ colon specimens could help resolve 
whether there is population based variation in normal CtBP expression pattern. 
Loss of ARF has been linked to tumor invasiveness and metastasis in a mouse 
skin cancer model 55. Evasion of apoptosis by tumor cells enables them to survive in an 
adverse microenvironment, and ultimately leads to invasion and metastasis 176, 177.  The 
ability of ARF to induce apoptosis by targeting CtBP may play a critical role in 
suppression of tumor invasion and metastasis, especially in tumors with p53 inactivation. 
Indeed, work from our lab has shown that CtBPs can promote the migration of cancer 
cells, and ARF can effectively inhibit CtBP2-mediated cell migration 109. The mechanism 
for this regulation reflects the wide variety of genes regulated by CtBPs. In this case, 
ARF/CtBP2 regulates cancer cell migration by transcriptionally regulating PTEN 
phosphotase (Appendix II, Figure A2.1), and in turn, the modulating activity of the PI3 
kinase pathway 109. Selective pressure for ARF silencing in human epithelial cancers 
could thus derive, in part, from a p53-independent role in promoting tumor-cell apoptosis 
via CtBP degradation during the process of invasion and metastasis.  
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Figures 
Figure 2.1 ARF interacts with CtBP.  
A. GST or GST-mArf fusion proteins were conjugated to glutathione-agarose beads and 
incubated with U2OS cell lysates. Bound, endogenous, CtBP2 was assayed by western 
blot. Input lane shows 10% of the cell lysate. GST and GST-mArf migration positions in 
a GST immunoblot are indicated by arrows. B. Schematic representations of domains in 
mArf and mapping CtBP interaction domain of Arf. Lysates of U2OS cells transfected 
with indicated mArf constructs were immunoprecipitated with CtBP2 antibody, followed 
by immunoblotting with anti-ARF antibody. C. CtBP interacts with ARF in transfected 
cells. U2OS cells were transfected with V5 tagged hCtBP2 and hARF. Cell lysates were 
immunoprecipitated with control IgG, or anti-V5 antibodies, followed by Western blot 
analysis with anti-V5, anti-CtBP1 or anti-ARF antibody.  
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Figure 2.2 p19ArfL46D and p14ARFL50D retains p53-dependent functions of ARF.   
A. Mutations within the CtBP binding region of ARF do not disrupt p53 stabilization 
function. U2OS cells were transfected with HA-p53, MDM2 and the mArf plasmid 
constructs. Indicated proteins were detected by immunoblotting.  B. Mutations within the 
CtBP-binding region of ARF do not grossly disrupt induction of G1 arrest. Mouse 3TC-
D1 cells with wildtype p53, were transfected with the mArf constructs and sorted cells 
were analyzed for cell cycle profile by propidium iodide staining and FACS after 48 hrs 
of transfection. C. Mutations in the hydrophobic domain of ARF which interacts with 
CtBP do not disrupt nucleolar localization. U2OS cells were transfected with indicated 
mArf constructs and cells were immunostained with ARF antibody. 
  
A 
C 
B 
49 
 
 
 
D-E. Mutation (L50D) within the hydrophobic region of p14ARF which interacts with 
CtBP2 does not disrupt p53 stabilization function. U2OS cells (D) were transduced with 
empty, ARF, and p14ARFL50D retroviruses and HCT 116 cells (E) were transiently 
transfected with the indicated expression constructs. The cell lysates were used for 
detection indicated proteins by immunoblotting after 24 hours of infection. F. L50D 
mutation in the CtBP-binding region of ARF does not disrupt nucleolar localization of 
ARF. U2OS cells were transfected with p14ARF and p14ARFL50D expression constructs and 
immunostained with ARF antibody after 24 hours of transfection. 
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Figure 2.3 ARF causes CtBP degradation.  
A. U2OS (ARF-silenced) cells were transfected with vector or mArf plasmids, followed 
by mock or UV treatment (UVC 10 J/m2) and CtBP2 levels were determined 6 hrs post 
UV treatment by immunoblot and B. relative CtBP2 protein level was quantified and 
normalization against GAPDH. C. hARF causes CtBP loss without additional stress. 
Lysates of HCT116 and HCT116;p53-/- cells obtained 24 hrs post-infection with Ad-lacZ 
or Ad-hARF were immunoblotted with ARF, CtBP2 or GAPDH specific antibodies. D. 
hARF does not affect hCtBP2 mRNA level. RT-PCR of RNA prepared from HCT116; 
p53 -/- cells infected with control or hARF retrovirus was carried out using CtBP2 and 
GAPDH specific primers. E. mCtBP2 is degraded by the proteasome in response to UV. 
MEFs (mArf + p53+) were incubated with or without proteasome inhibitor (MG132) for 
24 h after mock or UV (10 J/m2) treatment. Cell lysates were analyzed for changes in 
CtBP2 level by Western blotting, followed by densitometry normalized to a GAPDH 
loading control. F. hARFL50D does not degrade CtBP. HCT116 p53–/– cells were 
transfected with control vector, hARF, or L50D mutant expression plasmids, and 24 h 
after transfection, CtBP2, hARF, and GAPDH expression was detected by 
immunoblotting. 
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Figure 2.4 ARF-induced CtBP2 degradation requires a phosphorylation at S428  
A. Effect of S428 mutation to alanine on ARF-induced depletion of exogenous CtBP2. 
U2OS cells were cotransfected with the full-length CBP2 (CtBP2-V5) or S428A mutant 
CtBP2 (CtBP2-∆V5) expression plasmids and vector or ARF expression plasmid. Cell 
lysates were analyzed after 24 hrs of transfection by anti-V5, anti-ARF and anti-GAPDH 
immunoblot. B. S428A mutation does not affect ARF/CtBP2 interaction in vivo. U2OS 
cells were transfected with the indicated CtBP2 expression plasmids along with ARF 
expression plasmid. Lysates were immunoprecipitated with control (IgG) or anti-CtBP2 
antibodies, and the IPs immunoblotted with anti-ARF and anti-CtBP2 antibodies.   
A 
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Figure 2.5 ARF expression or CtBP depletion causes p53-independent apoptosis  
A. ARF induces p53-independent apoptosis.  24 hrs after infection with Ad-lacZ or Ad-
hARF, HCT116 wt or p53-null cells were labeled with FAM-DEVD-FMK and propidium 
iodide and assayed by FACS. The percentages of live cells in each sample with active 
caspase 3 were plotted. B. p14ARFL50D does not induce apoptosis. HCT116; p53-/- cells 
were infected with empty, ARF and L50D retrovirus were labeled for Annexin V-PE and 
7-AAD and analyzed by FACS. 
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Figure 2.6 CtBP and ARF regulated coordinately in human colon cancers.   
(A) Representative Immunoblot of protein Lysates from colonic adenocarcinomas 
resection specimens (T), including matching normal tissue (N) with CtBP1, CtBP2, ARF, 
and GAPDH specific antibodies.  (B) RT-PCR with the Total RNA isolated from same 
set of tissue samples as in (A), RT-PCR with CtBP2 and GAPDH specific primers. (C) 
The percentage of each groups of all tumor samples screened compiled in the table 
format, the p-value was calculated by applying Chi square test, p<0.00001, when 
compared the correlation between ARF and CtBP expression levels. 
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Materials and Methods 
Cell Culture and Transfections 
Human osteosarcoma cell line (U2OS) and human colon cancer cell line 
(HCT116: ARF silenced by promoter methylation) were grown in complete DMEM and 
McCoy’s 5A medium respectively. Medium was supplemented with 10% fetal bovine 
serum and 100 units/ml penicillin and streptomycin, and incubated in humidified 5% 
CO2 at 37oC. Expression plasmids were transfected using Fugene 111. 
 
Plasmid Constructions 
Full length CtBP2 was cloned from human lung carcinoma cDNA using 
pcDNA3.1 (Invitrogen), directional TOPO cloning, and specific sense 
(CACCATGGCCCTTGTGGATA) and antisense (TTGCTCGTTGGGGTGCTC) 
primers.  CtBP deletion mutants were constructed in pcDNA 3.1 using specific PCR 
primers. pCD-mArf was generated by insertion of PCR amplified mArf coding sequence 
into pCDNA3.   Missense and deletion mArf mutants were generated using PCR as per 
QuickChange protocol (Stratagene). A synthetic mArf gene with arginine codons recoded 
and optimized for bacterial usage was synthesized from overlapping oligonucleotides and 
PCR amplified prior to cloning into BamH1/EcoR1 sites of pGEX vector. The integrity 
of the plasmids and the coding sequences were confirmed by sequencing.  
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Antibodies, Western Blotting 
Antibodies used were as follows: CtBP1 and 2 (BD Transduction Laboratories), p19Arf 
(ab80; AbCam), p14ARF (Novus Biologicals), GST (Z-5; Santa Cruz), V5 tag 
(Invitrogen), HA (12CA5, Roche), GAPDH (Advanced Immunochemical Inc.), PARP 
(BD Pharmingen) and cleaved caspase 3 (Cell Signaling). Anti-rabbit IgG-HRP or anti-
mouse IgG-HRP conjugates (Amersham) were used with ECL detection (Amersham) for 
Western blots. 
 
GST Pull-Down Assays 
GST-mArf (codons optimized for E. coli) and GST were expressed in BL21 cells. 
Lysates from U2OS cells transiently transfected with CtBP full length and mutants were 
prepared as described 178 and incubated with GST or GST-conjugated mArf immobilized 
on glutathione-Sepharose beads. The beads were washed with wash buffer (10mM Tris 
pH8.0, 150 mM NaCl, 0.1% Triton –X-100, 2 mM MgCl2, 10µM ZnCl2, 10% glycerol) 
three times. Protein bound to beads was eluted with 20mM glutathione in elution buffer 
(10mM Tris pH8.0, 120 mM NaCl, 0.1% Triton X-100, 10% glycerol), separated by SDS 
PAGE and immunoblotted. 
 
Coimmunoprecipitation 
Cell lysates (100 µg of protein) from 1.5x107 cells in lysis buffer (20mM Hepes, 
10µM ZnCl2, 1mM MgCl2, 250 mM NaCl, 0.1% Triton X-100, 1mM DTT, 1mM 
PMSF, 10µg/ml Aprotinin and Leupeptin) were incubated at 4oC for 1 hr with specific 
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antibody-conjugated Sepharose used for immunoprecipitation. Beads were washed 3 
times in Wash Buffer (20mM Hepes, 10µM ZnCl2, 1mM MgCl2, 150 mM NaCl, 0.1% 
Triton X-100, 1mM PMSF, 10µg/ml Aprotinin and Leupeptin) followed by SDS-PAGE 
and Western blotting. 
 
UV Irradiation 
Cells were grown to 60% confluence in DMEM with supplements. The medium 
was removed and the dishes were exposed to UVC at a dose of 0-30 J/m2 using a 
Stratalinker (Stratagene).  The cells were collected 6 hrs post-treatment, washed with 
PBS and scraped in lysis buffer supplemented with protease inhibitors. The lysates were 
then analyzed by western blotting.  
 
Adenoviral Infections 
Ad-hARF 162 and Ad-lacZ high titer virus stocks were the generous gift of T. 
Kowalik. Cells (106) were plated in 6 well plates 24 hr before infection at confluency of 
50%. Cells were washed with PBS once and infected with the Ad-lacZ or Ad-hARF virus 
in serum free medium at an MOI of 100 at 37oC for 1 hr. Virus medium was removed and 
McCoy’s medium was then added, and the cells were collected at 24 hrs post-infection 
and either lysed for western blotting or stained for caspase detection. Caspa Tag TM 
Caspase-3/7 In Situ Assay kit (Chemicon International) was used for in situ detection of 
activated caspase 3 and 7 by FACS.  
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Immunofluorescence 
U2OS cells grown on cover slips were transfected with the indicated ARF 
constructs, and 24 hrs after transfection cells were fixed and immunostained with anti-
ARF antibody and anti-Rabbit IgG-rhodamine as described  153. 
 
Tumor Sample Analysis 
Whole tissue lysates were prepared using the PARIS® kit (Ambion Inc, TX). 
CtBP (both CtBP1 and CtBP2), ARF, GAPDH were immunoblotted using mentioned 
antibodies. The total RNA from each tumor and normal samples was prepared as per 
PARIS® kit (Ambion). RT-PCR was done using Stratascript ® RT kit. The primers used 
for RT-PCR were CTBP2- sense (132-155) 5’-CGAGACGAGAGTTTCATCAC CTTA-
3’ antisense (411-387)5’-GCGGATACCTTCACAAATTCTGTC-3’ and GAPDH sense 
(219-240) 5’-ATCACCATCTTCCAGGAGCGA-3’antisense (690-670) 5’-GCCAG 
TGAG CTTCCCGTTCA-3’. The Institutional Review Board (IRB) at University of 
Massachusetts Medical School approved this tumor sample study.   
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Chapter- III 
 
An ARF/CtBP2 complex regulates BH3-only gene expression and  
p53-independent apoptosis 
Abstract 
The ARF tumor suppressor exerts both p53-dependent and p53-independent 
functions. The corepressor C-terminal binding protein (CtBP) interacts with ARF, 
resulting in proteasome-mediated degradation of CtBP.  ARF expression can induce p53-
independent apoptosis in p53-null colon cancer cells, in a manner dependent on ARF 
interaction with CtBP.  Bik was uniquely identified in an apoptotic gene array as 
coordinately upregulated in colon cancer cells after either CtBP2 knockdown or ARF 
overexpression. ARF expression led to robust induction of Bik mRNA and protein 
expression, and this activity required an intact CtBP binding domain.  Analysis of the Bik 
promoter revealed binding sites for CtBP-interacting Basic Kruppel-like Factor (BKLF).  
A Bik promoter luciferase reporter was repressed by BKLF and CtBP2, and ARF 
reversed CtBP-associated repression. Chromatin immunoprecipitation analyses showed 
that CtBP is recruited to the Bik promoter largely by BKLF.  Expression profiling of 
BH3-only gene expression in ARF-expressing or CtBP deficient cells revealed that Bik 
was uniquely regulated by ARF/CtBP in colon cancer cells, whereas additional BH3 
proteins (Bim, Bmf) exhibited CtBP dependent repression in osteosarcoma cells.  ARF 
antagonism of CtBP repression of Bik and other BH3-only gene expression may play a 
critical role in ARF-induced p53-independent apoptosis and tumor suppression.  
61 
 
 
 
Introduction 
The tumor suppressor ARF is a product of the INK4a/ARF locus 10 that can act via 
p53-dependent or independent pathways 31, 148. ARF is frequently inactivated in a wide 
spectrum of human cancer types, including colorectal, breast, and pancreatic 
adenocarcinomas, malignant glioma, melanoma, and non-Hodgkin's lymphoma 169, 179. 
Germline homozygous knockout of Arf in mice results in the development of lymphomas 
and sarcomas similar to those observed in p53-deficient mice 31. Simultaneous 
inactivation of p53 and Arf results in a broader tumor spectrum and more aggressive 
tumors than are observed with either knockout alone, suggesting an additional 
mechanism for ARF tumor suppression apart from its canonical activation of p53 31. 
The transcription regulator CtBP has been identified as a specific target of the 
ARF tumor suppressor relevant to ARF’s ability to induce apoptosis in cells lacking p53 
68. ARF binds to CtBP, resulting in proteasome-mediated degradation and inactivation of 
CtBP 68. CtBP proteins act as transcriptional repressors in conjunction with a wide range 
of DNA binding transcription factors, and are regulated and activated as repressors by 
NADH binding to their dehydrogenase domains 180.  
CtBP1/2-null MEFs are hypersensitive to apoptosis in response to a wide variety 
of stimuli 70. Microarray analysis has shown that epithelial specific and proapoptotic 
genes are upregulated in these MEFs 70, though the precise mechanism that links CtBP to 
the suppression of pro-apoptotic gene expression is not known. Separate evidence 
suggests that siRNA mediated CtBP knockdown in human tumor cell lines is sufficient to 
induce apoptosis in the absence of additional stress 68. Though not yet proven, CtBP is 
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likely to be linked to tumor progression, as it promotes both cell survival and epithelial-
mesenchymal transition by repressing the transcription of both proapoptotic and epithelial 
genes 70.  
The effects of CtBP on cell survival have been linked specifically to its repression 
of pro-apoptotic BH3-only genes, of which Noxa and Puma were identified in a 
microarray comparison of wt and CtBP1/2 knockout MEFs 70.  Of note, the proapoptotic 
BH3-only proteins are critical mediators of death induced by cytokine deprivation, 
activated oncogenes, and various DNA damage stresses 118.  Their presumptive 
mechanism of action is to dissociate bax or bak from anti-apoptotic bcl-2 family proteins, 
allowing them to translocate to the outer mitochondrial membrane to form pores that 
allow the cytoplasmic release of cytochrome C 122, 123.  Of the 8 known BH3-only genes, 
Bid is a critical mediator of apoptosis mediated by death receptor signaling 124, Bim is the 
determinant of taxane responsiveness 125, Puma and Noxa are central mediators of p53-
induced apoptosis 126, and Bad regulates apoptosis mediated by growth factor/cytokine 
signaling 127. By contrast, the cellular apoptotic stimuli that act through Nbk/Bik, and the 
biologic functions of these genes in mammals, are not yet known 128.  
In this study, the BH3-only protein Bik was identified as an ARF and 
BKLF/CtBP-regulated gene, and a critical mediator of ARF-induced, CtBP2-mediated 
p53-independent apoptosis in colon cancer cells.  CtBP repression of Bik was directly 
antagonized by ARF, and CtBP was recruited to the Bik promoter via BKLF.  Apoptosis 
induced by CtBP deficiency in the absence of p53 was substantially impaired when Bik 
expression was also reduced by RNA interference.  Other BH3-only family members 
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besides Bik were co-regulated by CtBP in other cell types to suggest that p53-
independent ARF tumor suppression may involve regulation of different sets of BH3-
only proteins, dependent on tissue origin.  
 
Results 
Bik is upregulated after CtBP2 depletion or ARF overexpression 
To identify the mediators of ARF/CtBP2-induced p53-independent apoptosis, a 
human cDNA apoptosis microarray was interrogated with mRNA obtained from 
HCT116;p53-/- cells infected with control or ARF adenovirus 68 or treated with control or 
CtBP2 siRNA. Genes with more than a two-fold change (compared to control) after 
either CtBP2 depletion or ARF overexpression were considered for further investigation. 
Though a number of TNF pathway genes were induced after both ARF expression and 
CtBP2 silencing—none were common between the two conditions (Figure 3.1A).  The 
BH3-only gene Bik was the only common gene upregulated under both conditions 
(Figure 3.1A).  
In order to more quantitatively assess the effects of CtBP2 depletion and ARF 
overexpression on Bik expression, Bik mRNA and protein levels were analyzed in 
HCT116; p53 -/- cells 24 hrs after either depletion of CtBP2 using siRNA or ARF 
overexpression by retroviral infection (Figure 3.1B).  Real-time PCR analysis confirmed 
that Bik expression was increased upon either CtBP2 depletion (2.6-fold) or ARF 
overexpression (2.3 fold) in HCT116; p53-/- cells (Figure 3.1B). Similarly, the protein 
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levels of Bik were found to be upregulated in CtBP2 siRNA treated cells as compared to 
control siRNA treated cells (Figure 3.1C).  
 
CtBP2 interaction is required for ARF regulation of Bik 
Since the ability of ARF to interact with CtBP correlates with its ability to induce 
apoptosis in p53-null cells 68, Bik expression was analyzed in cells where ARF/CtBP 
interaction was either intact or abrogated. HCT116; p53 -/- cells infected with ARF, 
ARFL50D (CtBP interaction defective, however it retains p53 stabilization function and 
nucleolar localization of p14ARF, Figure 1.2D-F), or control retrovirus were analyzed for 
Bik protein levels by western blotting (Figure 1D). Both ARF and ARFL50D were 
expressed at similar levels (Figure 3.1D).  Bik was induced in ARF expressing cells, 
whereas ARFL50D expressing cells showed no Bik induction, similar to that observed for 
cells infected with empty virus (Figure 3.1D). Thus, the ability of ARF to interact with 
CtBP was required for its induction of Bik expression. 
 
Bik depletion rescues CtBP2-induced p53-independent apoptosis 
To further investigate the hypothesis that Bik functions as an important mediator 
of ARF/CtBP induced apoptosis, Bik and CtBP2 were simultaneously knocked down in 
HCT116; p53-/- cells and induced to undergo apoptosis upon UV treatment. Despite 
comprehensive screening for effective Bik-specific si- and shRNA sequences, the best 
knockdown of Bik that could be achieved was only partial, though two independent 
shRNA sequences were obtained (Figure 3.2A). Annexin-V and trypan blue stains 
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documented apoptotic fraction (Figure 2A) and viability (Figure 2B), and cell lysates 
were also immunoblotted to monitor for PARP and caspase 3 cleavage (Figure 3.2B).  
As expected, CtBP2 depletion led to increased Bik levels in cells with control 
shRNA, and even in Bik shRNA-expressing cells (Figure 3.2B).  The basal apoptosis rate 
in low-dose (20 J/M2) UV treated cells with control si and shRNA’s was 7%, and the 
overall non-viability rate was 12% (Figure 3.2C-D).  siCtBP2 induced a more than 
doubling of apoptotic fraction to 16% (p= 0.04) and non-viability to 27% (p= 0.01).  This 
effect was partially abrogated by shBik, with reduction of apoptotic fraction to 10% (7% 
basal level, p= 0.02) and non-viability to 17 % (12% basal level, p= 0.02; Figure 3.2C-
D). A second Bik shRNA yielded essentially similar effects in all assays (Figure 3.2C-D).  
Results with annexin and trypan blue staining were mirrored in the abundance of PARP 
and caspase 3 cleavage products (Figure 3.2B).  These data strongly support the 
hypothesis that Bik plays an important role in the induction of apoptosis after CtBP 
depletion in colon cancer cells.  The partial rescue of apoptosis by Bik knockdown would 
be consistent with the partial knockdown of its expression by shRNA, suggesting that a 
more robust knockdown might have further suppressed apoptosis closer to baseline 
levels.  However, the contribution of other proapoptotic proteins (BH3-only or other) to 
apoptosis in CtBP2 deficient cells cannot be completely ruled out.  
ARF is generally not expressed at detectable levels in normal cells, and it is not 
induced by environmental stresses, except oncogenic signals. However, its ability to 
inhibit CtBP may potentiate the effects of stress such as UV or hypoxia. Additional 
stresses such as UV (20J/m2) or hypoxia in human colon cancer induced more robust 
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apoptosis when they express ARF than control (15% vs. 26% with UV and 15% vs. 32% 
in hypoxia), whereas ARFL50D expression in these cells did not enhance stress-induced 
apoptosis. These findings are consistent with the hypothesis that, ARF’s interaction and 
inhibition of CtBP is required for it to both induce and potentiate apoptosis in cells 
lacking p53 (Figure 3.2E).  
 
ARF/CtBP regulation of the Bik promoter through BKLF recognition elements 
In silico analysis of the Bik promoter for recognition sites relevant to transcription 
factors that recruit CtBP as a corepressor revealed 4 sites with an exact match to BKLF 
(KLF8/ZNF741/BKLF3)  recognition elements, including a tandem repeat 181 (Figure 3.3 
A, B).  Examination of the upstream (-1 to -2000) promoter regions of the other 7 known 
BH3-only genes revealed obvious BKLF sites upstream of the Noxa, Puma, Bmf and 
Bim genes (Figure 3.3B).  To test the hypothesis that the recruitment of CtBP by BKLF 
represses Bik promoter activity, Bik promoter luciferase reporters containing either all 
wildtype BKLF binding sites,  or with the two tandem sites mutated, were transfected 
into U2OS cells with BKLF, ARF, and CtBP2 expression vectors.  Either BKLF or 
CtBP2, alone, repressed the wildtype promoter about 2.5-fold (p <0.01) (Figure 3.3C) 
while there was no effect on the mutant reporter (Figure 3.3D). CtBP2/BKLF 
coexpression further repressed Bik promoter activity another 2-fold (p <0.05) (Figure 
3.3C).  Overexpression of ARF had no effect on BKLF repression of Bik promoter 
activity (compare 1st and 3rd yellow bars; Figure 3.3C), but when ARF was cotransfected 
with CtBP2 and BKLF, ARF caused a near complete reversal of CtBP2-associated 
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repression (compare 2nd and 4th yellow bars; Figure 3.3C).  Reversal of CtBP2-mediated 
repression by ARF is consistent with the finding that ARF degrades and/or sequesters 
CtBP in the nucleolus, abrogating its repressor activities 68.  Thus, BKLF elements are 
crucial for CtBP/BKLF-mediated repression of the Bik promoter.  Consistent with ARF’s 
known effects on CtBP, ARF reversed CtBP2/BKLF-mediated repression of the Bik 
promoter, but had no effect on BKLF-mediated repression in the absence of CtBP2.  
 
CtBP2 is recruited to the Bik promoter 
Previous studies have demonstrated that CtBP2 binds to BKLF and regulates 
expression of genes downstream of BKLF recognition elements 182.  To address whether 
CtBP is directly recruited to the Bik promoter, CtBP2 chromatin immunoprecipitation 
(ChIP) was performed using two sets of promoter specific primers including one set 
(PS1) that amplified a fragment which is near to the single BKLF binding site in the 
distal part of the Bik promoter or a PS2 set of primers amplified a fragment 
encompassing the 2 tandem BKLF binding sites in the Bik promoter (Figure 4A-B). 
Additionally, a negative control primer set (NS) that amplified a fragment 10 kb upstream 
of the promoter was also tested and E-cadherin promoter primers were utilized as a 
positive control 111. CtBP2 was recruited to both the Bik (PS2) and E-cadherin promoters 
in chromatin obtained from H1299 human lung carcinoma cells, whereas no signal was 
seen in either of the CtBP2 ChIPs with control (NS) or PS1 primers that amplified 
fragments with no BKLF sites, nor was any signal detected in control or no antibody 
ChIPs with PS1 or PS2 primers (Figure 3.4B-C). 
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To test whether CtBP2 recruitment to the Bik promoter required BKLF, a CtBP2 
ChIP assay was performed using chromatin from cells where BKLF was stably depleted 
using shRNA (knockdown ~50% by RT-PCR; Figure 3.4D) and primers specific for the 
Bik and E-cadherin promoters or control Bik intergenic region primers.  When compared 
to control, BKLF shRNA expression led to increased Bik expression as determined by 
immunoblot, and as predicted by the reporter assays (Figure 3.4E, 3.3C).  As expected, 
CtBP2 was present at the Bik and E-cadherin promoters in control shRNA expressing 
cells, but in the absence of BKLF, CtBP2 was no longer recruited to Bik promoter, 
despite remaining present at the E-cadherin promoter (Figure 3.4F). The specificity of the 
ChIP signals were bolstered by the lack of signal either in the control antibody ChIP or in 
the CtBP2 ChIP with control intergenic region Bik primers (Figure 3.4F). Thus, CtBP2 is 
recruited to the Bik promoter, largely via BKLF (Figure 3.4G).  
 
Differential regulation of BH3-only pro-apoptotic genes  
Though Bik plays an important role in ARF-induced p53-independent apoptosis 
in HCT116;p53-/- cells, several other BH3-only genes have been previously shown by 
genomic techniques (in MEFs) to be regulated by CtBP1 and 2 70.  In order to study the 
potential regulation of the family of BH3-only genes by CtBP in cells of either epithelial 
or mesenchymal lineage, the mRNA and protein levels of Bik, Bim, Bmf, Noxa, and 
Puma were determined in HCT116;p53-/- colon carcinoma cells and U2OS osteosarcoma 
cells after treatment with control or CtBP2 siRNA.  As predicted by the apoptosis gene 
array (Figure 3.1), Bik was the only BH3-only genes induced >2-fold at RNA level in 
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HCT116;p53-/- cells, while U2OS cells were more permissive for BH3-only gene 
expression with 2-2.5 fold induction of Bik, Bim, and Bmf, and 1.5-fold induction of 
Puma and Noxa after CtBP2 knockdown (Figure 3.5A, D). Where mRNA induction was 
>= 2-fold, protein expression was also increased as seen for Bik in HCT116;p53-/- cells, 
and Bik, Bim, and Bmf in U2OS cells. 
ARF expression would be expected to phenocopy CtBP2 knockdown for 
regulation of BH3 gene expression, based on its antagonism of CtBP  68.  Indeed, ARF 
expression resulted in Bik induction as previously seen (Figure 1), but had little effect on 
protein levels of the other BH3-only proteins (Bim, Bmf, Puma and Noxa) in 
HCT116;p53-/- colon carcinoma cells (Figure 3.5C).  ARFL50D expression had little effect 
on the abundance of any BH3-only protein, including Bik, as already has been noted. 
Thus, ARF expression phenocopies the specific impact of CtBP2 depletion on BH3-only 
gene expression in colon cancer cells, supporting the hypothesis that ARF/CtBP 
complexes directly control BH3-only gene expression and thus, p53-independent 
apoptosis, in a cell-type specific manner. 
 
Discussion 
ARF overexpression, or depletion of CtBP2, induced mRNA and protein 
expression of the proapoptotic BH3-only gene Bik.  Induction of Bik required ARF/CtBP 
interaction, and the induction of apoptosis by UV and CtBP2 depletion required 
physiologic levels of Bik.  CtBP2 was recruited to the Bik promoter by the transcription 
factor BKLF, and ARF abrogated CtBP/BKLF repression of the Bik promoter.  
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Furthermore, the pattern of BH3-only gene regulation by CtBP appeared to depend on 
cell type context, suggesting that p53-independent tumor suppression by ARF may be 
more relevant to certain tumor types than others.  
Bik is a proapoptotic protein of the ‘BH3-only’ family. Expression of Bik triggers 
apoptosis in breast, lung, prostate, and colon carcinoma, as well as glioma and 
melanoma-derived cell lines 123, 183, 184, 185, 186. Consistent with a role for Bik in tumor 
suppression, 22p13.3, which contains Bik, is commonly deleted in human colorectal and 
breast cancers  187, and Bik mutations have been identified in renal cell carcinoma 188.  
By contrast, in non-malignant cells, Bik functions may overlap with other BH3 proteins, 
as Bik is not essential for normal development 140.  In vitro, Bik knockout mouse T and B 
cells also did not exhibit an apoptotic defect, though epithelial cells were not examined in 
that study 140. The absence of a mouse phenotype does not necessarily exclude a role in 
native tumor suppression, however, as the Bik knockout mice and cells were not exposed 
to an oncogenic stress to reveal a more subtle tumor or apoptotic phenotype 140. 
Functionally, Bik is not a direct initiator of apoptosis, but acts upstream of the 
pro-survival Bcl-2- family members 189.  Recent studies also suggest that Bik plays a role 
in oxidative stress induced apoptosis 190. Bik binds directly to BCL-2 or BCL-XL via its 
BH3 domain, and inactivates their antiapoptotic functions. Therefore, an increase in Bik 
levels lowers the cellular apoptotic threshold by blocking the anti-apoptotic function of 
BCL-2-family proteins 191. A competing hypothesis suggests that Bik might also activate 
the downstream effectors Bak or Bax directly to cause apoptosis 142. Further study on the 
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apoptotic pathway downstream of Bik will be required to fully understand the role of Bik 
in CtBP2 induced p53-independent apoptosis.  
CtBP has been described as a transcriptional regulator of apoptosis as it 
transcriptionally repress multiple proapoptotic genes, such as Noxa, Puma and PERP 70. 
Many of these genes are also known transcriptional targets of p53. However, CtBP 
regulation of Bik, as shown in the current work, is p53-independent and likely acting 
through BKLF instead of p53.  BKLF can recruit mCtBP2, via its PXDLS motif 192 to the 
β-globin  promoter  element, resulting in repression 75. We have observed that CtBP2 is 
also recruited by BKLF to tandem CACCC elements in the Bik promoter, since 
knockdown of BKLF abrogated CtBP2 recruitment to the Bik promoter in colon cancer 
cells and mutation of the tandem repeat abrogated CtBP2 repression of a Bik reporter. 
The involvement of other related KLF transcription factors (KLF1/EKLF: erythroid 
Kruppel-like factor, KLF2/LKLF: lung Kruppel-like factor, KLF4/GKLF: gut-enriched, 
KLF5/IKLF: intestinal-enriched, KLF7/UKLF: ubiquitous KLF, among others) in CtBP2 
recruitment cannot be ruled out in other cell contexts, as many KLF’s function in a tissue 
dependent manner 193.  
CtBP senses the metabolic state of the cell due to a requirement for NADH 
binding to its dehydrogenase domain to activate repressor function 180.  CtBP has been 
linked to the hypoxic activation of cell migration, and this effect may be due to its 
repression of other non-apoptosis pathway genes such as PTEN 70, 109.  Since hypoxia is 
fundamentally linked to tumor progression, CtBP may serve as a critical oncogenic link 
by which hypoxia leads to activation of key malignant characteristics such as enhanced 
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cell survival and increased motility and invasion 108, 109, 194. Based on this hypothesis, the 
current data would support the idea that Bik might be especially important in tumor 
suppression in hypoxic cells, and moreover, ARF loss or mutation should specifically 
enhance cell survival in hypoxia by release of CtBP from any negative control.  This, 
then, may also explain why ARF can so profoundly impact tumor progression in vivo 
with its loss promoting increased tumor aggressiveness 55, 108, 195. 
This study demonstrates a role for the ARF/CtBP complex in the transcriptional 
regulation of Bik, and this pathway contributes to the apoptotic response in human colon 
cancer cells. The ARF/CtBP interaction may explain many of the p53-independent 
apoptotic effects of ARF. This work raises the possibility that tumorigenesis is enhanced 
in the absence of ARF due to an apoptotic defect in a parallel ARF-regulated tumor 
surveillance system that is completely independent of p53. With further understanding of 
the cellular consequences of ARF/CtBP interaction there is the distinct possibility of 
manipulating this pathway either through ARF-mimetics or CtBP inhibitors for 
therapeutic benefit in the substantial fraction of tumors that lack p53 and/or ARF 
function. 
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Figures 
Figure 3.1 Bik is upregulated upon ARF overexpression or CtBP depletion in 
p53-null human colon cancer cells. 
 A. Total RNA isolated from HCT116; p53-/- cells following either ARF overexpression 
or CtBP knockdown was subjected to an apoptotic gene array (Superarray) analysis. The 
fold change in relative gene expression level was calculated by using GEArray 
Expression Analysis Suite (SA Biosciences). B. RNA prepared from HCT116; p53−/− 
cells with above treatment was to carry out quantitative real time PCR using Bik and 
GAPDH specific primers. Graph represents GAPDH-normalized average fold change of 
Bik in treated cells.  Error bars represent +/- 1 standard deviation (S.D.) C. CtBP2 
regulates Bik expression. HCT116; p53-/- cells were treated with control or CtBP2 
siRNA duplexes, and CtBP2, Bik and GAPDH levels were determined by 
immunoblotting 24 hrs after transfection. D. CtBP2 interaction with ARF is required for 
regulation of Bik expression. HCT116; p53 -/- cells were infected with vector, hARF, or 
hARF (L50D) mutant lentivirus for 24 hrs. Cell lysates were analyzed for Bik, GAPDH, 
and ARF levels by immunoblotting.  
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Figure 3.2 Bik knockdown rescues ARF/CtBP2 induced p53-independent 
apoptosis.  
A. HCT116; p53-/- cells stably infected with Tet-inducible shBik1 and shBik2 
lentiviruses and induced with 2 µg/ml doxycycline for 24 hours and immunoblotted for 
GAPDH and Bik protein levels. B.  HCT116; p53-/- cells with stable Bik knockdown 
were transiently transfected with either control or CtBP2 siRNA, and then 20J/M2 UV-C 
treated. After 24 hours of transfection and UV treatment, apoptosis markers (cleaved 
caspase 3 and cleaved PARP), CtBP2, Bik and GAPDH levels in each of the treatment 
conditions were determined by immunoblotting. C. Apoptosis Assay: HCT 116: p53-/- 
cells were stably infected with shBik1 and shBik2 lentiviruses and transiently transfected 
with either control or CtBP2 siRNA.  All cells were exposed to 20J/M2 UV-C. After 24 
hours of transfection and UV treatment, apoptosis was determined by Annexin V-PE/7-
AAD staining. D. Cell Viability Assay: The percentage of viable cells was determined 
after treatment as in (C) by staining cells with 0.4 % Trypan Blue (Sigma). E. ARF-
induced apoptosis upon stress. HCT116 p53-/- cells were infected with empty (Ev), ARF 
and L50D retrovirus. After 24 hours of infection, cells were exposed to either 20J/m2 of 
UV or hypoxia (0.5 % oxygen in hypoxia chamber) for 24 hours. Apoptosis was 
determined by Annexin V-PE and 7-AAD staining and FACS analysis.  All experiments 
were performed in triplicate and the results expressed as Mean ± 1 S.D with the p-value 
<0.05.    
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Figure 3.3 ARF/CtBP regulates the Bik promoter through BKLF recognition 
elements.  
BH3-only genes contain BKLF recognition elements. A. Diagram of BKLF recognition 
elements in the Bik promoter.  B. Alignment and BKLF element localization in the Noxa, 
Puma, Bim, Bmf and Bik promoters. C. ARF antagonizes CtBP/BKLF repression of the 
Bik promoter. Bik (pGL3-Bik-luc) was cotransfected with expression constructs for ARF, 
BKLF, or CtBP2 into U2OS cells along with a control reporter plasmid expressing 
Renilla luciferase (pRL-TK). D. A Bik-luciferase reporter with mutation of the tandem 
BKLF sites was cotransfected with expression constructs for ARF, BKLF, or CtBP2 into 
U2OS cells along with a control reporter plasmid expressing Renilla luciferase (pRL-
TK). Normalized firefly luciferase activity from three independent experiments was 
averaged, and error bars indicate +/- 1 S.D and with the p < 0.005.  
A 
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Figure 3.4 BKLF mediated recruitment of CtBP to the Bik promoter.  
A. The location of the primers (arrows) relative to BKLF binding sites, primer set 1 (PS-
1) is near to distal BKLF binding site, PS-2 is flanking the tandem BKLF binding site at -
631, primer set NS is 10 kb downstream of start site of Bik promoter.  B and C. ChIP 
assay for CtBP. H1299 chromatin was immunoprecipitated with control IgG or CtBP 
antibody (B). Immunoprecipitated and input DNAs were amplified by PCR using primers 
sets PS 1 and 2 (C and D) specific for the BKLF binding region of the Bik promoter (-
693 to –551), non-specific (NS) primers that amplify a fragment ~10 kb  upstream of the 
Bik transcription start site (-9500 to –9300; negative control), or E-cadherin promoter 
primers  111. D. Efficacy of BKLF shRNA. shRNA targeting BKLF or GFP was stably 
expressed in H1299 cells. RT-PCR was performed to determine the knockdown of BKLF 
mRNA with GAPDH mRNA level as an internal control. RT-PCR products were 
electrophoresed in an agarose gel and stained with ethidium bromide.  E. BKLF 
regulation of Bik expression.  shBKLF or shGFP were stably expressed in HCT116: p53-
/- cells, and protein levels of GAPDH and Bik determined by immunoblotting. F. CtBP 
recruitment to the Bik promoter requires BKLF.  CtBP2 or control (No Ab) ChIP was 
performed with chromatin obtained from shGFP or shBKLF expressing cells.  
Immunoprecipitated DNA was analyzed by PCR using primers specific for Bik promoter, 
non-specific and E-Cadherin promoter primers as in (A). G. Model of BKLF/CtBP2 
mediated transcription regulation of Bik expression 
B 
A 
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Figure 3.5 Regulation of BH3-only genes by ARF and CtBP.  
RNA isolated after CtBP2 or control siRNA treatment of HCT116; p53-/- (A), or U2OS 
(D) cells was subjected to RQ-PCR using GAPDH, β-Actin and Bik, Bim, Bmf, Puma 
and Noxa primers. Cell lysates from HCT116; p53-/- (B), or U2OS (E) cells treated with 
control or CtBP2 siRNA and HCT116; p53-/- cells infected with either empty, ARF or 
ARFL50D retroviruses (C) were analyzed for GAPDH, Bik, Bim, Bmf, Puma and Noxa 
protein levels by immunoblotting.  
B C 
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Materials and Methods  
Cell culture and transfection 
HCT116 human colon cancer cells (ARF silenced) 196 with targeted deletion of 
p53 were grown in McCoy’s 5A medium. U2OS (human osteosarcoma) and H1299 
(human lung cancer) cells were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100µg of streptomycin 
and incubated in humidified 5% CO2 at 37°C. Mammalian expression plasmids were 
transfected using Fugene 111, and siRNA duplexes were transfected with Oligofectamine 
(Invitrogen), with a siRNA concentration of 40 nM. After retro/ lentiviral infections, cells 
were selected using puromycin at 2µg/ml.  
 
Plasmids, siRNAs, shRNA and viral expression vectors 
V5-tagged CtBP2 expression plasmid pcDNA-V5-CtBP2 has been described 68.  
PcDNA-T7ARF was generated by insertion of a PCR amplified ARF coding sequence 
with a T7 tag sequence embedded in the 5’ primer into pCDNA3. The expression plasmid 
containing the CtBP2-binding defective allele of (L50D) of ARF was generated from 
PcDNA-T7ARF using PCR as per the Quikchange protocol (Stratagene). pBabe-Puro 
ARF and pBabe-ARFL50D were used to generate retroviruses. pLenti-ShGFP, pLenti-
ShBik, pLenti-Puro-hARF and pLenti-Puro-hARFL50D were generated using Gateway 
cloning System® (Invitrogen). Retro/lentiviruses were produced in HEK293T cells by 
transfecting ARF constructs along with packaging constructs (pol/gag and VSVG). 
siRNA sequence for human CtBP2 was AAGCGCCUUGGUCAGUAAUAG. shBKLF: 
83 
 
 
 
CTGGTCGATATGGATAAACTCA; shBik1: GGAGAAATGTCTGAAGTAA; shBik2: 
ACACTTAAGGAGAACATAA.  
 
Immunoblotting  
Cells were lysed in lysis buffer (20 mM HEPES pH 7.4, 0.5% Triton X-100, 2 
mM MgCl2, 10µM ZnCl2, 2 mM NEM, 1 mM PMSF, 240mM NaCl) containing protease 
inhibitor tablets 111. Antibodies used were as follows: CtBP2 (BD Biosciences), hARF 
(Novus), T7 tag (Novagen), GAPDH (Advanced Immuno), Noxa (Imgenex), Bik, Puma, 
Cleaved Caspase (Cell Signaling) PARP (Santa Cruz). Anti-rabbit IgG-horseradish 
peroxidase and anti-mouse IgG-horseradish peroxidase conjugates (Jackson 
Immunoresearch) were used with ECL detection (GE Healthcare) for immunoblotting.  
 
cDNA array analysis of apoptosis-associated genes 
Total RNA was extracted from HCT116; p53-/- cells after CtBP2 knockdown or 
ARF infection using RNeasy (Qiagen). Biotin labeled cDNA probes were generated with 
5µg of total RNA using TrueLabeling-AMPTM 2.0 kit (SuperArray) according to 
manufacturer’s instructions. cDNA probes were purified using an ArrayGrade cDNA 
cleanup kit (SuperArray). Biotinylated-cDNA probes were denatured, hybridized to 
GEArray® Human Apoptosis microarray (OHS-012, SuperArray) as per manufacturer’s 
instructions. After overnight incubation at 60°C, the membranes were washed 
successively in 2x SSC-1% SDS and 0.1x SSC-0.5 % SDS for 15 min each. The arrays 
were developed using chemiluminescence detection kit (SuperArray) and the acquired 
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images were analyzed by using GE Array Expression Analysis Suite 1.1. The basic raw 
data was normalized for empty spot and housekeeping genes (GAPDH and β-actin).   
 
Real-time quantitative PCR 
 mRNA transcripts for human Bik, Puma, Noxa and GAPDH were analyzed by 
real-time quantitative reverse transcription-PCR (RQ-PCR) using SYBR green (Applied 
Biosystems) and an ABI 7300 (Applied Biosystems). Relative amounts of the mRNA 
transcripts were calculated using the CT method with GAPDH and b-actin mRNA as 
internal references. The primer sets used were Bik (sense: TCCTATGGCTCTG 
CAATTGTCA, antisense: GGCAGGAGTGAATGGCTCTTC), Bim (sense: GCCCC 
TACCTCCCTACAGAC, antisense: ACTGTCGTATGGAAGCCATTG), Bmf (sense: 
CCACCAGCCAGGAAGACAAAG, antisense: TGCTCCCCAATGGGCAAGACT), 
Noxa (Sense: CTGCAGGACTGTTCGTGTTCA, antisense: GGAACCTCAGCCTCCA 
ACTG), Puma (sense:  GGGCCCAGACTGTGAATCC, antisense: CGTCGCTCTCTCT 
AAACCTATGC), B-Actin (Sense: GCTCCTCCTGAGCGCAAGT, antisense: TCGTCA 
TACTCCTGCTTGCTGAT).RT-PCR for BKLF was done using the following BKLF 
primers: sense BKLF 5’AGGTGGCTCAATGCAGGTAT3’; antisense  BKLF 5’CATGG 
GCAGAGACTGCACTA3’. GAPDH primers were sense 5’ATCACCATCTTCCAGGA 
GCGA-3’; antisense 5’-GCCAGTGAGCTTCCCGTTCA3’. 
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Apoptosis and cell viability Assays 
For apoptosis analysis, cells were trypsinized after 48 hrs of transfection, washed 
with cold PBS, stained with Annexin V-PE and 7-AAD according to the manufacturer’s 
instructions (BD Biosciences, USA), and subjected to FACS analysis. For viability 
analysis, cells were trypsinized, mixed with trypan blue solution and counted in the 
hemocytometer.   
 
Bik promoter-luciferase reporter assay 
  A 1.9 kb region of human Bik promoter (−1710 to +203) was amplified by PCR 
from pBLCAT2 181 and inserted into the firefly luciferase reporter pGL3 (Promega). 
U2OS cells were transfected with pGL3-Bik and a control plasmid expressing the Renilla 
luciferase (pRL-TK), CtBP2, ARF,  and BKLF using Fugene 111. The expression of 
reporter genes was determined by Dual Luciferase assay (Promega) after 36 hours of 
transfection.  
 
Chromatin immunoprecipitation assay (ChIP) 
Cells were plated for 24 hrs and approximately 108 cells were used for each ChIP 
assay. Cells were washed once in PBS and were treated with 1% formaldehyde in cold 
PBS for 10 min at 4°C with continuous shaking. Glycine (final concentration of 125mM) 
was added to quench the formaldehyde for 5 min at 4°C with continuous shaking. Cells 
were then harvested and washed twice with ice-cold PBS. Nuclei were isolated by 
incubating the cells in nucleus isolation buffer (5 mM PIPES pH 8.0, 85 mM KCl, 0. 5% 
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NP40) for 20 to 30 min on ice. The nuclei were harvested at 4°C by centrifuging the cell 
suspension at 7,000g for 5  min and resuspended in 2 ml of RIPA buffer (150 mM NaCl, 
1% v/v Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8. 0, 5 mM 
EDTA) containing protease inhibitors. Chromatin   was fragmented to approximately 200 
to 700 bp by sonication. Nuclear debris was removed by centrifuging the lysates at 4°C 
for 15 min at 14,000 rpm. The lysate was precleared by incubation with the protein G 
Sepharose beads for 30 min at 4°C. Immunoprecipitation was performed overnight at 4°C 
with the respective antibody. Protein G Sepharose beads were added and the 
immunocomplexes were allowed to bind to the beads for 2 h at 4°C. The beads were 
washed once each with RIPA buffer, RIPA buffer with 500 mM NaCl, 
immunoprecipitation wash buffer (10 mM Tris HCl  pH 8.0, 250 mM LiCl, 0. 5% NP40, 
0. 5%  Sodium deoxycholate, 1 mM EDTA) and finally with Tris-EDTA. Beads were 
resuspended in 200 µl of elution buffer (50 mM Tris HCl, pH 8.0, 10 mM EDTA, 1% 
SDS) with Proteinase K and incubated overnight at 55°C. DNA was extracted by phenol-
chloroform, precipitated in the presence of glycogen by ethanol, allowed to air dry, and 
dissolved in TE buffer pH 8.0. Immunoprecipitated DNA was diluted tenfold to keep the 
PCR in the linear range of amplification. The following set of primers was used to 
amplify different regions of the genes indicated: For the promoter region (-551bp  to -
693bp) of Bik where BKLF binding sites are present PS2; 5’TATACCAG 
GGCTGGAGTTAGGTCC3’and 5’-CTCACGTGCAGACCTGGTGAG A-3; primers set 
near distal BKLF binding site PS1 (-1504 to -1647); sense 5’-CTGCTAATGTTTACTG 
AACATCTC-3’ and antisense 5’- AAATTGAGACAGGGTGGTAAAG-3’  Non specific 
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primers (-9.5 kb to -9.3 kb) upstream of BKLF binding sites 5’CCTAAGAAGCTGGCC 
ACAGCTC3’ and 5’ CCATCATGTTGGCCAGAATGGTC TC3’; E-Cadherin primers 
5’TAGCCTGGCGTGGTGGTGTGCACCTG3’ and 5’GTGCGTGGCTGCAGCCAGG 
TGAGCC3’ 111.   
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Chapter-IV 
 
Functional analysis of p19ArfL46D knock-in mouse primary cells  
 
Introduction 
The p16INK4a and p19Arf tumor suppressor proteins encoded by the INK4a/ARF 
locus 10 exert their function in distinct anti-cancer pathways: p16INK4a regulates RB, and 
p19Arf regulates p53. The p16INK4a transcript is encoded from exons 1α, 2 and 3, whereas 
p19Arf is encoded by exons 1β, 2 and 3. Although both genes utilize common exons 2 and 
3, they are controlled by distinct promoters, and exon 2 is transcribed in an alternate 
reading frame in p19Arf. Therefore, p16Ink4a and p19Arf are completely divergent in protein 
sequence, and by inference, function. Ectopic expression of p19Arf in cells lacking 
p16INK4a induced a G0/G1 arrest, indicating p19Arf functions independently of p16INK4a 10. 
Expression of p19Arf is upregulated upon hyperproliferative signals from Ras, Myc, E1A 
and E2F, and through the inhibition of Mdm2, results in either p53-dependent apoptosis 
or cell cycle arrest 12, 13, 14. ARF can also suppress the proliferation of cells defective for 
p53 by antagonizing c-myc and E2F proteins 31, 56. The increased incidence of epithelial 
tumors in Arf-null mice compared to p53-null mice, and the broader tumor spectrum 
observed in triple-null (p53/Arf/Mdm2-null) mice compared to that observed with loss of 
any one of these genes, has provided genetic evidence in the mouse to support the 
existence of an ARF tumor suppressor activity that is independent of p53.  
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ARF is generally not detectably expressed in normal cells or during mouse 
embryogenesis, and genetic targeting and disruption of the Arf gene has no effect on 
development 23, 38. p19Arf, p16INK4a, p53, and p21 are induced with increasing passage in 
primary mouse embryonic fibroblasts (MEFs) in culture, and their accumulation 
inversely correlates with the cell proliferation rate 12. Arf-null MEFs are immortal and 
can be transformed by oncogenic ras without a requirement for collaborating oncogenes 
such as adenovirus E1A or myc 23. Arf-null MEFs display an increased rate of cell 
proliferation and exhibit reduced basal levels of p21Cip1, a p53-regulated gene and a 
potent senescent cell-derived growth inhibitor 23, 197. Paradoxically, they express higher 
levels of p16INK4a than their wildtype counterparts. Thus, ARF appears to exert its effects 
on growth control in fibroblasts mainly upstream of p53.  
The idea that ARF might have tumor suppressor functions that are independent of 
p53 and Mdm2 has led to the identification of abundance of ARF interacting proteins 10, 
50, 68. ARF is a very unusual protein with more than 20% arginine residues, and likely 
unstructured when not complexed (Straza and Grossman unpublished), and it thus may 
interact promiscuously with several proteins. Thus, the challenge is how to validate bona 
fide ARF interacting proteins and distinguish them from non-specific candidates. ARF 
expression is induced by oncogenic stress, by ablation of p53, or by the non-
physiological conditions of tissue culture in primary MEFS. Therefore, the molecular 
mechanism that governs ARF expression and its functional effects in cell culture may 
differ from its behavior in vivo. Thus, the development of mouse models is imperative to 
validate and understand the functional significance of ARF’s interactions.  
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The transcriptional corepressor CtBP2 has now been identified and validated in 
cell based assays as a putative target of the p53-independent tumor suppression function 
of ARF. ARF interacted with and induced the proteasome-mediated degradation of CtBP, 
leading to the induction of p53-independent apoptosis 68. A conserved hydrophobic 
region within Arf (residues 32-51 in mouse Arf) was identified as critical for CtBP 
interaction. A point mutation within this domain (L46D in mouse; L50D in human) 
abrogated CtBP interaction and the induction of apoptosis. Both ARF-induction of CtBP 
degradation and p53-independent apoptosis was dependent on its ability to interact with 
CtBP. Thus, CtBP proteins represent putative targets of ARF’s p53-independent tumor 
suppressor activity.  
The robust test for the function and physiologic relevance of the ARF/CtBP 
interaction is to develop a mouse model where the interaction is abrogated by mutation of 
either ARF or CtBP. Given that Arf is a single gene and the minimal region required for 
ARF/CtBP interaction has been mapped, while CtBP is a gene family with two highly 
conserved members, ARF would appear to be the logical gene to target in a mouse model 
designed to investigate function of the ARF/CtBP interaction. The p19ArfL46D mutation is 
defective in cell culture for CtBP-interaction and degradation, but retains properties of 
nucleolar localization, MDM2 binding, and p53 activation. Thus, the L46D mutation 
might be an ideal candidate mutation for generating a knock-in mouse. However, the 
possibility that other proteins may interact with this region of ARF and the functional 
consequences cannot be ruled out in this genetic model.  
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To investigate the physiologic function of ARF/CtBP interaction in tumor 
suppression in vivo, a p19ArfL46D knock-in mouse was generated by incorporating the 
point mutation into exon1β of INK4a/ARF locus. Analysis of p19ArfL46D   
(heterogzygote and homozygote) primary mouse embryonic fibroblasts (MEFs) revealed 
that the L46D point mutation in p19Arf increased the proliferation rate of MEFs, providing 
evidence in primary cells that the abrogation of p53-independent tumor suppressor 
activity of Arf leads to uncontrolled cell growth. However, L46D homozygous MEFs 
proliferate slower than Arf-null MEFs confirming the robustness of the residual p53-
dependent effects of ARF. Although L46D (heterozygote/homozygote) MEFs grew with 
an increased proliferation rate, they failed to undergo spontaneous immortalization, 
suggesting that the p53-dependent functions of ARF remains intact in Arf L46D cells. 
Further, L46D homozygous and L46/- hemizygous MEFs demonstrated increased 
migration rates compared to their wildtype counter parts but, migrated slower than Arf-
null MEFs consistent with contributions from both the CtBP and p53 pathways to this 
ARF function.   
 
Results 
Generation of p19ArfL46D knock-in mice 
 To investigate the specific contribution of the Arf/CtBP2 interaction to Arf tumor 
suppressor function in vivo, the L46D point mutation, which is defective for CtBP-
interaction and degradation in cell culture, was introduced in to the mouse germline. To 
generate a p19ArfL46D targeting construct, a 1.0 kb genomic region containing exon1β was 
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amplified and the L46D point mutation with an Mse I unique restriction site was 
introduced into exon1β using PCR primers (Figure 4.1) and Quickchange protocol 
(Stratagene). 3.0 kb of 5’ and 3’ intronic genomic sequence flanking exon1β was PCR 
amplified and cloned 5’ and 3’ to the mutated exon1β. The targeting construct also 
contained a loxP flanked pGK-neo neomycin drug resistance marker to facilitate positive 
selection (Figure 4.1). The p19ArfL46D knock-in targeting construct was electroporated into 
AB2.2 embryonic stem (ES) cells, and underwent positive selection (G418). Four 
hundred ES cell clones were screened for homologous recombination of the target allele 
using Southern blot analysis. EcoRV digested genomic DNA, and a 3’ flanking probe was 
used to identify the four clones that correctly displayed both the wildtype 30 kb and the 
mutant 17.3 kb bands (Figure 4.2). Further analysis with a 5’ flanking probe 
demonstrated that those four ES cell clones correctly underwent homologous 
recombination by yielding 30 kb and 12.7 kb bands (Figure 4.2).  
 Three correctly targeted ES cell clones were injected into blastocysts, and 
subsequently transferred into foster mothers, resulting in four high-degree chimeras (2 
each of 60% and 90%). Crossing the 90% chimeras to C57BL/6 females gave rise to 
agouti F1 progeny, and Southern blot (Figure 4.3A) and PCR/restriction enzyme MseI 
digestion (Figure 4.3B) analysis demonstrated germline transmission of the p19ArfL46D-flox 
neo mutant allele.  
 p19ArfL46D-flox-neo heterozygous mice were viable, fertile, and appeared 
phenotypically normal. In order to excise the neo cassette from the heterozygous L46D 
allele, p19ArfL46D-neo mice were bred to protamine-Cre (PC3-Cre) transgenic mice 198. 
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p19ArfL46D/+ heterozygous mice were generated from this cross, and heterozygous mice 
were intercrossed to obtain p19ArfL46D/L46D homozygous mice with the neo cassette 
excised. Excision of the neo cassette was confirmed by PCR using neo cassette flanking 
primers that yielded a larger fragment than wildtype in excised mice due to the residual 
loxP and polylinker sequence left behind. The wildtype allele yielded 107 bp fragment 
whereas, the homozygous L46D yielded a 210 bp fragment, and heterozygotes yielded 
both of these fragments (Figure 4.3C). The presence of the mutant allele was also 
confirmed by sequencing a PCR amplified fragment of exon1β. Genotyping of 50 pups 
from a heterozygous mating demonstrated that 14 were wild type, 24 were L46D/+, and 
12 were L46D/L46D, consistent with the expected Mendelian ratios. L46D heterozygous 
and homozygous mice were indistinguishable from their littermates phenotypically. 
Western blot analysis of p19Arf protein harvested from mouse embryonic fibroblasts 
generated for each genotype revealed that the homozygous knock-in mutant retained the 
expression of p19Arf protein similar to that observed in wildtype littermate MEFs (Figure 
4.4B).  
 
Regulation of cell proliferation by the L46D point mutation 
 Mouse embryonic fibroblasts were explanted from wildtype, L46D heterozygous, 
L46D homozygous and Arf-null embryos to compare the proliferation rates of cells of 
different genotype. Two independent lines from each genotype were grown in 6 cm 
plates, and the cells counted every 24 hours for a 8 day period. Analysis of the growth 
rate of these MEFs revealed that the L46D homozygous MEFs proliferated significantly 
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faster than wildtype MEFs, but not as fast as Arf-null MEFs (Figure 4.4A). The L46D 
homozygote MEFs’ proliferation rate was similar to that of p19Arf+/- MEFs (data not 
shown) suggesting that the L46D mutation may not affect p53-dependent functions, 
which was consistent with the effect of L46D on p53-dependent ARF functions in cell 
based assays (Figure 2.2).  
Arf-null MEFs grew with a higher proliferation rate with decreased 
p21Cip1expression as reported previously 23 (Figure 4.4B). To determine the expression 
pattern of CtBP2, p16INK4a, p19Arf, p21Cip1 and p53, the whole cell lysate harvested 
from first 4 passages was used from wildtype, Arf+/-, Arf-null, L46D/- hemizygous, 
L46D heterozygous, and L46D homozygous MEFs. There was no significant difference 
in CtBP2 protein levels in Arf-null and L46D MEFs, may be due to the requirement for 
an additional UV stress for efficient degradation of CtBP2 68. Further, there was no 
significant difference in the expression levels of p53, p16INK4a, and p21Cip1 in L46D 
homozygous, heterozygous and hemizygous MEFs, confirming that L46D does not affect 
p53-dependent functions (Figure 4.4B). These findings also suggest that p53-independent 
and CtBP2 dependent pathways might both regulate cell growth. However, to completely 
rule out the possibility of a contribution of p53 to the L46D phenotype, homozygote 
L46D/p53-null MEFs might be compared directly to L46D homozygote MEFs. This 
effect on cell growth may be completely due to cell proliferation, as MEFs does not 
easily undergo apoptosis under normal cell culture conditions. However, further analysis 
including BrdU incorporation and cell cycle analysis should be performed to completely 
rule out the contribution of apoptosis. 
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Immortalization of p19ArfL46D MEFs 
 Spontaneous immortalization is an extremely rare event in human cells, however 
rodent cells spontaneously immortalize at much greater rates. Cellular immortalization of 
MEFs has been achieved by the inactivation of the p53 or Rb pathways 199, 200. To 
determine the contribution of the ARF/CtBP interaction to cell immortalization, we 
carried out a 3T9 (modified 3T3) cell immortalization assay. MEFs harvested from 
wildtype, L46D/+, L46D homozygous, L46D/- hemizygous, Arf+/-, Arf-null embryos 
were cultured continuously as per the standard protocol 201. As previously reported, Arf-
null MEFs demonstrated a rapid rate of cell growth throughout the entire assay relative to 
wildtype MEFs 22 (Figure 4.4). L46D homozygous MEFs grew with a slower 
proliferation rate than Arf-null cells, but faster than wildtype MEFs, and they did finally 
enter senescence after the 15th passage. Thus, unlike Arf-null MEFs, which are 
phenotypically similar to p53-null MEFs in immortalization assays 202, ArfL46D/L46D MEFs 
showed high rate of proliferation initially but did not ultimately immortalize. 
Interestingly, L46D/- hemizygous cells continued to grow at much faster rate than L46D 
or wildtype MEFs and undergone spontaneous immortalization (Figure 4.4A), suggesting 
that there is crosstalk and cooperation between p53-dependent and p53-indpendent 
pathways controlled by ARF.   
 
Loss of CtBP interaction with ARF results in increased cell migration in MEFs  
 To study the effect of ARF/CtBP interaction on cell migration in MEFs, a 
transwell cell migration assay was performed using MEFs harvested from wildtype, Arf-
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null, L46D/- (hemizygous), L46D heterozygous, and homozygous embryos. It has been 
shown that CtBP2 promotes cell migration and invasion, and hARF effectively inhibits 
cancer cell migration by targeting CtBP2 for proteasome-mediated degradation 68, 109. 
Consistent with the previous report 203, Arf-null MEFs migrated significantly faster than 
wildtype and other genotype MEFs used in this assay (Figure 4.6). The MEFs explanted 
from embryos carrying an L46D mutation demonstrated an increased migration rate 
compared to littermate wildtype MEFs, but slower than that of Arf-null MEFs (Figure 
4.6). Interestingly, L46D/- hemizygous MEFs showed an increased migration rate 
compared to that of wildtype or L46D homozygote MEFs (Figure 4.6). These data 
suggest that the CtBP-binding domain of ARF contributes to ARF’s ability to regulate 
cell migration.  
  
Discussion   
p53-null and Arf-null mice develop highly penetrant lymphomas and sarcomas 
with mean latencies for survival of 20 and 32 weeks respectively 25, 152. In mice lacking 
p53, T-cell lymphomas are most common, with the remainder being sarcomas 27. In 
contrast, Arf-null mice primarily develop sarcomas with a lower incidence of 
lymphomas, as well as a low incidence of carcinomas and gliomas 23, 152. The increased 
tumor latency in Arf-null mice might allow the shift in tumor spectrum and emergence of 
tumor types such as carcinomas and gliomas, which were not normally seen in p53-null 
mice. Further, the incidence of carcinomas was increased in Arf/p53 double-null and 
Arf/p53/Mdm2 triple-null animals suggesting the existence of Mdm2- and p53-
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independent tumor suppressor functions for ARF. However, the physiologic mechanisms 
of p53-independent tumor suppressor functions remain obscure. CtBP2 has been 
identified as a target for the p53-independent functions of ARF. ARF inhibits CtBP2 by 
inducing its degradation, sequestering it in the nucleolus, and CtBP’s functional 
inhibition results in the induction of apoptosis and a reduction in cancer cell migration 68, 
109. 
In this study, we have generated the p19ArfL46D knock-in mice and primary mouse 
embryonic fibroblasts to study the role of ARF/CtBP interaction in cellular growth 
control to migration in a native physiologic setting. Primary MEFs were used to study the 
effects of L46D mutation on the regulation of cell survival and cell migration. MEFs 
explanted from L46D homozygote embryos showed an increased rate of cell 
proliferation. However, L46D MEFs failed to undergo spontaneous cell immortalization, 
though they continued to grow at a higher proliferation rate into late passage, than 
wildtype littermate MEFs, suggesting that L46D mutation may contribute to cell 
proliferation but not induce spontaneous immortalization. Further, L46D MEFs migrated 
faster than wildtype and more interestingly, L46D/- (hemizygous) MEFs migrated 
significantly faster than L46D homozygous MEFs, suggesting p53-independent functions 
of Arf also contribute to the regulation of cell migration.  
 Mouse embryonic fibroblasts from Arf-null embryos proliferated at significantly 
faster rates than their wildtype counterparts as previously reported 23. L46D MEFs 
showed a higher proliferation rate than wildtype MEFs but slower than Arf-null MEFs. 
More interestingly, L46D/- hemizygous MEFs proliferated at rates similar to that of 
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Arf+/- MEFs and they continued to grow for more passages than L46D homozygous 
MEFs, suggesting that negative growth regulation by the p53-independent functions of 
ARF is not as robust as p53-dependent growth regulation. The increased proliferation rate 
of Arf-null MEFs was linked to a reduction in the expression of p21Cip1, a p53 responsive 
gene, though the Arf-null MEFs displayed increased levels of p16INK4a. In contrast, there 
was no significant difference in p16INK4a or p21Cip1 expression levels in L46D MEFs, 
compared to their wildtype counterparts. However, the contribution of other pro-survival 
ARF/CtBP2 transcriptional targets such as p15INK4a or other uncharacterized targets to the 
growth effects of L46D mutation cannot be ruled out.  Although L46D MEFs continued 
to grew with a higher proliferation rate than wildtype MEFs, they did not undergo 
spontaneous immortalization, which is a p53-dependent function, suggesting that the 
L46D mutation does not greatly affect the p53-dependent function of Arf in mouse 
primary cells as has been previously reported in cancer cell lines 68. Interestingly, L46D/- 
hemizygous MEFS showed some inclination to undergo spontaneous immortalization 
compared to L46D/L46D MEFs, implying that both p53-dependent and p53-independent 
functions of Arf may exert additive effects on spontaneous immortalization. To rule out 
completely the possibility that L46D may contribute to the regulation of cell growth 
through p53, MEFs should generate from L46D/p53-null and compared to the single 
homozygotes background.    
 p19Arf has been shown to regulate cell migration via p53-dependent and p53-
independent pathways 108, 109, 203. Studies from our lab demonstrated that CtBP2 promotes 
cancer cell migration under hypoxic conditions and ARF inhibits CtBP2-mediated cancer 
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cell migration by targeting CtBP2 for degradation 68, 109. Genetic disruption of Arf in 
MEFs enhances cell migration as shown previously 203. Abrogation of Arf/CtBP2 
interaction in MEFs (L46D) also increased cell migration significantly compared to 
wildtype MEFs but not as robustly as Arf deletion. L46D/- hemizygous MEFs 
demonstrated faster cell migration than L46D homozygous MEFs, confirming the 
contribution of both p53-dependent and p53-independent functions of Arf towards 
regulation of cell migration.  
 The data from our study demonstrated that p53-independent tumor suppressor 
function of ARF contribute to the inhibition of cell growth in primary mouse cells. 
Furthermore, abrogation of Arf/CtBP2 interaction correlated with increased cell 
migration. Further work will be needed to better understand and characterize the role of 
p15INK4a or PI3 kinase pathway components or uncharacterized transcriptional targets in 
ARF/CtBP regulation of cell proliferation, migration, apoptosis and tumorigenesis. 
Although analysis of primary mouse cells revealed the expected cellular phenotypes, the 
tumor spectrum, size, and latency of tumor formation and survival of L46D mice in 
comparison to Arf-null, p53-null, and wild type, would reveal the functional significance 
of ARF/CtBP interaction at an organismal level.   
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Figures 
Figure 4.1 Targeting strategy for the p19ArfL46D knock-in mouse.   
Schematic of the INK4b-ARF-INK4a locus and the p19Arf L46D knock-in construct. A 1.0 
kb fragment containing exon 1β and cloned into pBluescript-II and L46D point mutation 
and Mse I restriction site was introduced as per mutagenesis protocol (Stratagene). 
Approximately 3.0 kb of 5’ and 3’ homologous sequence was amplified by PCR and 
cloned sequentially into pBluescript-ArfL46D construct. Finally, the neo cassette was 
inserted into the construct.  
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Figure 4.2 Screening of targeted p19ArfL46D ES cells.  
The DNA isolated from targeted ES cells was digested overnight with EcoRV and 
Southern blot analysis was performed. Probing with the 5’ flanking probe yields a 30 kb 
band corresponding to the wildtype allele, and due to an additional EcoRV site in the neo 
cassette, the L46D mutant yield 17.3 kb band. Similarly, probing with a 3’ flanking probe 
yields a 30 kb wildtype band and a 12.7 kb band for the mutant allele.   
102 
 
 
 
Figure 4.3 Genotyping of the p19ArfL46D knock-in mouse. A. Tail DNA isolated 
from wildtype, L46D heterozygous and homozygous knock-in mice was digested with 
EcoRV and southern blot analysis was performed. Probing with the 5’ flanking probe 
yields a 30 kb band corresponding to a wildtype allele, and due to an additional EcoRV 
site in the neo cassette, the mutant yields 17.3 kb band. Similarly, probing with a 3’ 
flanking probe yielded a 30 kb band for the wildtype and a 12.7 kb band for the mutant 
allele. B. A 1.0 kb fragment containing Exon1β was PCR amplified and digested with 
Mse I restriction enzyme. Wildtype DNA yielded 910 bp and 120 bp bands whereas 
DNA from a heterozygous pup yielded 680 bp, 230 bp and 120 bp bands. A1 and A2 are 
L46D heterozygous mice. C. PCR to confirm neo cassette excision: DNA isolated from 
pups generated by crossing PC3-Cre and L46D-neo was used in PCR using neo cassette 
flanking primers. Wildtype yielded the expected 107 bp band; whereas L46D 
homozygous yielded a 120 bp band and heterozygotes yielded both the expected bands.  
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Figure 4.4  Regulation of cell proliferative by p19ArfL46D  
A. Two independent mouse embryonic fibroblasts (MEF) cell lines each of the Arf-null, 
L46D homozygous, L46D heterozygous, littermate wildtype of Arf-null (indicated by 
asterisk) and L46D littermate wildtype genotypes were plated in triplicate in 6 cm plates 
and the proliferation rate was analyzed by counting cells over 6 days. Each data point 
represents average of triplicate plates and three counts in each plate with p-value between 
Arf-null/WT p=0.001 and L46D/WT, p=0.001. B. MEFs isolated from the indicated 
genotypes were harvested up to four passages and immunoblotted with the indicated 
antibodies.   
 
   
A 
B 
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Figure 4.5 Immortalization of p19ArfL46D cells.  
Cell Immortalization (3T9) assay. At 3-day intervals, the total number of cells per two 
independent lines of MEFs from each genotype were determined prior to repassage of the 
cells at 3x106 cells per 10cm plates. Each data point represents the average of number of 
cells from triplicates of two independent lines for each genotype. Wildtype littermate 
MEFs from the Arf-null and L46D backgrounds (two lines) were included in the assay as 
controls.  
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Figure 4.6 Transwell cell migration assay  
MEFs explanted from embryos with wildtype, Arf-null, L46D homozygous and L46D/- 
hemizygous genotypes were used in a transwell cell migration assay. 3T3 conditioned 
medium was used as chemo attractant and the transwells were coated with collagen. A 
representative field for each genotype is shown (A). The number of cells migrated/field 
was an average of the number of migrated cells counted from five microscopic fields 
after 1 hour of incubation at 37 oC from duplicate experiments and error bars indicate +/- 
1 S.D (B). 
 
   
A 
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Materials and Methods 
Generation of p19ArfL46D knock-in targeting construct 
 A 1.0 kb genomic fragment containing exon1β Xho I-Sal I was generated by PCR 
and cloned into pBluescript II KS (+) vector. The L46D point mutation and a restriction 
enzyme Mse I site was introduced using Quickchange protocol for mutagenesis 
(Stratagene). A 2.3 kb Kpn I-Xho I genomic fragment of 5’ homology and a 2.4 kb Sal I-
Bgl II genomic fragment 3’ homology respectively were generated by PCR and then 
added into pBluescript-exon1βL46D. To enable positive selection, PGK neomycin cassette 
was inserted upstream of exon 1β. The entire construct was sequenced using several 
primers to confirm the presence of L46D mutation and other region of genomic locus to 
enable homologous recombination.  
 
Generation of p19ArfL46D knock-in ES cells and chimeras 
The p19ArfL46D knock-in construct was linearized at a unique Not I site, gel 
purified and electroporated into AB2.3 embryonic stem (ES) cells.  After positive 
selection with G418, clones were picked and screened by Southern blot analysis. ES cell 
DNA was isolated and digested with EcoRV overnight, electrophoresed on 1 % agarose 
gel, transferred on to Hybond® nitrocellulose membrane and probed with 5’ flanking 
probe. Putative positive clones additionally screened with the 3’ flanking probe. The 
L46D point mutation was confirmed by PCR and restriction digestion with Mse I.  
Correctly targeted ES cell clones were microinjected into C57BL/6 blastocysts and 
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implanted into pseudo pregnant foster mice using standard protocol. Chimeric offsprings 
are identified by presence of agouti coat color and the highest degree chimeras (> 70 %) 
were mated to C57BL/6 females to assay for germline transmission of the p19ArfL46D 
mutant allele.   
 
Mice 
In order to remove neomycin resistance cassette, the p19ArfL46D heterozygous 
female mice with neo cassette intact were crossed to PC3-Cre 129/C57 male mice.  
Excision of the neo cassette was confirmed using flanking PCR primers M1 (5’-
AGATGGGCGTGGAGCAAAGATG-3’) and M6 (5’-CTCACTGTGACAAGCGAGGT 
GAG).  All mice were maintained and used, in accordance with federal guidelines and 
those established by Institution Animal Care and Use Committee (IACUC) at University 
of Massachusetts Medical School. Mice were monitored regularly for signs of any 
abnormalities or disease. 
 
Cell Culture  
 Mouse embryonic fibroblasts (MEFs) were generated from D13.5-15 day 
embryos as described previously  204. All studies were conducted using low passage 
MEFs (passage 2-4), maintained in a 5% CO2 incubator at 37 0C in a Dulbecco’s 
modified Eagles medium (DMEM) supplemented with 10 % fetal bovine serum, 
penicillin and streptomycin.  
 
108 
 
 
 
 
 
Cell Proliferation Assay 
In order to determine the rates of cell proliferation, two lines of wildtype, Arf-
null, Arf-heterozygous, ArfL46D hemizygous, L46D heterozygous and L46D 
homozygous MEFs were seeded at 1x105 cells per well in a 6well plate. Cells were 
harvested and counted every 24 hours using Z1 Coulter Particle Counter (Beckman 
Couture, FL). Cell proliferation assay was repeated twice in triplicates for each genotype 
and average number of cells was plotted in line diagram.  
 
Immortalization Assay (3T9 Assay) 
 To determine the rate of spontaneous immortalization of MEFs, a 3T9 assay was 
carried out as described 201. Briefly, 3x106 cells from wildtype, L46D heterozygous and 
L46D homozygous MEFs were plated in complete DMEM on 10 cm plates every three 
days.  Two separate lines of MEFs for each genotype were maintained in total of 3 plates 
with 3x106 cells (9x106 cells). Cells were trypsinized prior to counting and plated at a 
density of 3x106 cells per 10 cm plate every three days. 
 
Cell Migration Assay 
 Cell migration assays were performed as previously described 205. Briefly, 6.5 mm 
Transwell chambers (8µm pore size; Costar, Cambridge, MA) were coated on the 
underside with 25µg/ml type I collagen for 2hrs at 37oC or overnight at 4oC. Cells from 
109 
 
 
 
two lines for each genotypes were trypsinized, washed in serum-free medium and 
resuspended in DMEM medium with 0.25% heat inactivated BSA at a concentration of 
106/ml. 105 cells were transferred to the top chamber of the transwell and 3T3 conditional 
medium was added to the lower chamber.  Migration was allowed to proceed for 1 hour 
at 37 oC. Non-migrating cells were removed from the top surfaces of the Transwell 
membranes using cotton swabs. The membranes were then fixed in methanol and stained 
with DAPI.  Average number of cells migrated was calculated by counting cells in five 
microscopic fields in triplicate Transwells for each lines.  
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Chapter-V 
 
Final thoughts and Future Directions 
 
Cancer cells acquire a common set of properties such as unlimited proliferation, 
resistance to apoptosis, and self-sufficiency, through a multistep, mutagenic process. 
Cancer cells gain these phenotypes by reactivating and modifying several cellular 
programs that are normally active during development. Cancer evolves through random 
mutations and epigenetic changes in oncogenes and tumor suppressors that alter cellular 
processes such as cell proliferation, migration, apoptosis, and differentiation, and selects 
those cells that can tolerate and survive under deleterious circumstances. In addition to 
frequent mutations in a number of oncogenes and tumor suppressors, there are large 
numbers of low frequency changes that contribute to tumorigenesis.  Not surprisingly, 
individual mutations in as many as 20% of all kinases can play an important role during 
oncogenesis 206, although it remains to be elucidated, whether mutations in other gene 
classes will also enhance tumor formation as much as that of oncogenes or tumor 
suppressors. The CtBP family proteins are targets of tumor suppressor proteins for 
inhibition, and thus, may qualify as candidates for deregulation during tumorigenesis.   
 
The ARF tumor suppressor gene is inactivated in a large number of human 
cancers. Several lines of evidence from murine and human systems suggest that ARF 
exerts tumor suppressor functions apart from p53. Most interesting and important is that 
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tumor progression is enhanced in the absence of ARF, due to an apoptotic defect in a 
tumor surveillance system that is completely independent of p53. Thus, I sought to 
identify the mediators of p53-independent functions of ARF. From my dissertation 
research, we have demonstrated that ARF/CtBP2 interaction explains many of the p53-
independent effects of ARF. The ARF tumor suppressor protein appears to destabilize 
CtBP, allowing cancer cell to evade apoptosis. Indeed, CtBP levels are elevated in 
majority of human colorectal adenocarcinomas, and inversely correlated with ARF 
expression. Furthermore, we identified BH3-only genes such as Bik, Bim, and Bmf, as 
novel targets and the critical mediators of ARF-induced, CtBP2-mediated p53-
independent apoptosis in colon cancer cells (Figure 5.1). Studies from our lab also 
revealed that CtBP2 promotes cancer cell migration by transcriptionally regulating PTEN 
phosphotase, and in turn, activating the PI3-kinase pathway. Introduction of ARF can 
therefore effectively inhibits CtBP2-mediated cell migration by abrogating CtBP2-
mediated regulation of the PI3-kinase pathway 109. Lastly, we have identified, and 
generated a knock-in mouse model with, a functional point mutation in p19Arf (L46D; 
Leucine to Aspartic acid) that is defective for CtBP2-binding, degradation, and induction 
of apoptosis. The cells harvested from knock-in mice revealed a cell growth and cell 
migration phenotype. Taken together, these findings suggest that CtBPs are novel 
downstream targets for p53-independent tumor suppression by ARF.  
  
 The molecular mechanism by which ARF affects the functions of its interacting 
proteins remains unclear, though the functional consequence is invariably inactivation  
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148. Indeed, ARF interacted with CtBP2 through a novel, conserved hydrophobic domain 
(37-51 residues in p19Arf) in exon 1β and induced proteasome-mediated degradation of 
CtBP2, leading to apoptosis in cells lacking p53 68. No known functions of ARF have 
been assigned to this conserved hydrophobic region of ARF. The point mutation in this 
region of ARF (L46D in p19Arf and L50D in p14ARF) both physically and functionally 
abrogated ARF/CtBP2 interaction. Though ARF inactivated CtBP2 functionally by 
altering its metabolic stability, the molecular mechanism by which ARF induced CtBP 
degradation remains unclear. Moreover, the point mutation in this conserved region of 
ARF did not affect p53-dependent functions of ARF suggesting that a novel function of 
ARF was inactivated by the L46D/L50D mutations.  
 
CtBP family proteins are modulators of several essential cellular processes 
including cell proliferation, cell migration and apoptosis 116. CtBP protein levels are 
tightly regulated by the ubiquitin-proteasome system. CtBP1 becomes ubiquitinated upon 
UV irradiation and this is dependent on phosphorylation of S422 by HipK2 kinase 69. 
Studies from our lab showed that CtBP2 appeared to be constitutively ubiquitinated, and 
its ubiquitination status was unaffected by ARF expression 68. Our preliminary studies on 
the mechanism of CtBP2 degradation demonstrated that phosphorylation at S428 (site for 
the stress sensitive kinase HipK2) was required for both UV-induced and ARF-induced 
degradation. The mutation that abolishes phosphorylation at this site rendered CtBP 
resistant to ARF-induced or UV-induced degradation. However, phosphorylation at 
serine 428 was not required for ARF and CtBP2 interaction, suggesting that 
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phosphorylation may play an important role in CtBP2 degradation in steps beyond ARF 
interaction. That step could be a delivery of ubiquitinated substrates to the proteasome 
and CtBP2 phosphorylation at S428 residue may aid in this process. The possibility that 
the S428 phosphorylation site may be targeted by other kinases that might regulate CtBP 
degradation under conditions other than UV-induced stress would be worth exploring. 
The effects of a phosphorylation mimic mutant of CtBP2 (S428D) on ARF-induced 
CtBP2 degradation would be worth considering for future studies. Further, the S428A 
mutant may serve as an ideal candidate for generation of knock-in mouse model with a 
CtBP2 mutation, which disrupts ARF/CtBP2 interaction at a functional level. Compared 
to p19Arf, p14ARF had a robust destabilizing effect on CtBP without any additional 
stress such as UV treatment. Thus, the minor amino acid sequence difference between 
human and mouse ARF might contribute to the difference in their ability to destabilize 
CtBP2. Further analysis using deletion mutants or chimeric ARF proteins would be 
required to address these functional differences between human and mouse ARF.  
 
ARF-induced CtBP2 degradation depends on a functional 26S proteasome, but 
does not involve ARF-dependent modulation of CtBP ubiquitination 68. CtBP1, but not 
CtBP2 is sumoylated, as CtBP2 lacks the SUMO conjugation consensus site, suggesting 
that SUMO modification is unlikely to play a role in ARF-induced CtBP2 degradation. 
Thus, the promotion of CtBP degradation in the absence of alteration in ubiquitination by 
ARF raises the important question of whether ARF plays the role of a ‘proteasome 
adaptor’. A previous report 167, along with our data, suggested that ARF interacts with the 
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S6a (TBP-1) ATPase subunit of the 19S proteasome regulatory particle (Appendix-I). 
Further, ARF and S6a coeluted with the 26S proteasome complex, but not with the 20S 
core particle of the proteasome assembly (Appendix-I). This finding implies that ARF, 
like other proteasome adaptor proteins such as hPLIC and Rad 23, may serve as a 
‘receptor’ for the proteasome that recognizes ubiquitinated substrates that are ready for 
degradation 168. Thus, it will be critical to determine whether CtBP2 and other ARF 
targets, such as E2F or NPM, interact with the proteasome in an ARF-dependent manner. 
Even though ARF interacts with a proteasome subunit, and coeluted with the proteasome 
regulatory assembly, it may still interact with the proteasome indirectly through a third 
protein, such as another proteasome adaptor or receptor. Our preliminary data with 
interaction studies using GST-S6a and p14ARF revealed that S6a and ARF interact 
directly. However, direct interaction of ARF with the proteasome should be determined 
using purified proteasomes and ARF. Ultimately, the biochemical link between ARF, 
CtBP, and the proteasome that results in CtBP degradation can be established by 
attempting in vitro proteasome degradation of CtBP2 with reconstitution of the reaction 
components. The potentially novel function of ARF as a ‘proteasome adaptor’ would 
explain its ability to inactivate its interacting proteins mainly by destabilizing them.  
 
 ARF expression in cells lacking p53 enhanced CtBP2 degradation resulting in 
induction of apoptosis. CtBP depletion using specific siRNA was alone sufficient to 
induce apoptosis, suggesting that ARF acts upstream of CtBP in this pathway. Moreover, 
repletion of CtBP in ARF expressing cells rescued cells from ARF-induced apoptosis, 
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confirming a direct role for CtBP in the apoptosis pathway activated by ARF in the 
absence of p53 68. CtBP2 functions as an antiapoptotic protein by transcriptionally 
repressing proapoptotic genes  113. Inactivation of CtBP2 by ARF may result in 
abrogation of this transcriptional regulation, and in turn, induction of apoptosis. The 
CtBP2 target genes may therefore function as the mediators of ARF-induced p53-
independent apoptosis.  
  
CtBP-null mouse embryonic fibroblasts (MEFs) are hypersensitive to apoptosis, 
and microarray analysis of these cells revealed that there was significant upregulation of 
proapoptotic genes including the BH3-only gene Noxa 70. We have identified BH3-only 
genes Bik in colon cancer cells and Bik, Bim, Bmf in osteosarcoma cells, as critical 
mediators of ARF-induced p53-independent apoptosis. Bik is a proapoptotic protein, 
which triggers apoptosis in breast, lung, prostate, colon adenocarcinoma, glioma, and 
melanoma derived cell lines. Consistent with its role in tumor suppression, the Bik locus 
(22p13.3) is commonly deleted in human colorectal and breast cancers 187. Bik mutations 
have been identified in renal cell carcinoma 188. By contrast, in non-malignant cells, Bik 
function may overlap with that of other BH3-only proteins, as Bik is not essential for 
normal development in mouse 143. ARF overexpression, or depletion of CtBP2, induced 
mRNA and protein expression of BH3-only genes. The induction of BH3-only genes also 
required ARF/CtBP2 physical interaction, and the induction of efficient apoptosis by UV 
and CtBP2 depletion required physiologic levels of Bik. CtBP2 regulation BH3-only 
genes expression required the cooperation of the DNA-binding transcription factor Basic 
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Kruppel-like Factor (BKLF). However, simultaneous depletion of Bik and CtBP2 using 
RNAi, only partially rescued the apoptotic phenotype in colon cancer cells, suggesting 
that there might be more mediators of apoptosis after CtBP2 depletion, including other 
BH3-only genes that might be involved in this pathway in a cell-specific and context-
dependent manner. Moreover, the involvement of other KLF transcription factors (EKLF: 
erythroid Kruppel-like factor, KLF2: Lung Kruppel-like factor, GKLF: gun-enriched 
Kruppel-like factor, UKLF: ubiquitous Kruppel-like factor) in CtBP2 recruitment to the 
target genes promoters cannot be ruled out. Many of the KLF factors are known to 
function as transcriptional repressors in a tissue-dependent and context-dependent 
manner 193.    
 
ARF is transcriptionally silenced in a variety of human carcinomas including 
colorectal adenocarcinomas. ARF’s target CtBP2 interacts with a wide range of 
transcription factors involved in developmental processes and tumorigenesis, such as 
AML1/Evi-1, MLL (mixed lineage leukemia) and AML1/FOG2 fusion proteins. CtBP, in 
turn, contributes to leukemiogenesis by cooperating with these oncogenic fusion proteins 
to promote abnormal hematopoietic growth and differentiation 95, 207, 208. The data 
reported in this dissertation are relevant to understanding the development and 
progression of, at least, human colorectal cancer. There is an inverse correlation between 
ARF and CtBP2 expression levels in human primary colorectal adenocarcinomas, with 
the majority of tumors displaying elevated levels of CtBP2 with no detectable ARF. This 
supports the idea that CtBP may function as a cellular proto-oncogene. However, analysis 
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of a larger sample size, and other tumor types, including melanoma, breast cancer, and 
tumors of nervous system, would yield valuable information about the contribution of the 
ARF/CtBP2 interaction to tumorigenesis. Most of these tumors may select for ARF 
silencing, in part, to inactivate its ability to degrade and inactivate CtBP proteins.  
 
CtBP proteins are uniquely sensitive to cellular metabolic conditions due to their 
intrinsic dehydrogenase activity and ability to bind NAD+/NADH. Given that ARF is 
activated under conditions of oncogenic stress which frequently induce reactive oxygen 
species 209, the dehydrogenase domain may serve as a further sensor to determine whether 
the conditions are correct for ARF to induce CtBP degradation or not. Thus, a 
combination of both ARF expression and altered metabolic state might be required to 
induce CtBP degradation, apoptosis, and inhibition of migration/invasion (Figure 5.1).  
Indeed, studies from our lab suggest that the NADH-binding region of CtBP2 is required 
for the promotion of cancer cell migration under hypoxic conditions. CtBP has been 
linked to the hypoxic activation of cell migration, due to its transcriptional repression of 
other non-apoptotic pathway gene such as PTEN 70, 109. Further, intact interaction of 
ARF/CtBP2 was essential for the inhibition of cell migration by ARF. Since hypoxia is 
fundamentally linked to malignant tumor progression, CtBP may serve as a critical 
oncogenic link by which hypoxia leads to activation of key malignant features such as 
enhanced cell survival, increased motility and invasion 108, 109, 194. The promotion of 
hypoxic cell migration by ARF inactivation may also serve as a potent selective force for 
the epigenetic silencing of ARF expression early in tumorigenesis. Indeed, analysis of a 
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p53/Arf-double null mouse hepatocellular cancer model suggests that Arf can block both 
migration and invasion in vitro in a p53-indepenendent and CtBP2-dependent manner. 
ARF loss or mutation should specifically enhance cell survival in hypoxia by release of 
CtBP from any negative control and this then, may also explain why ARF can also so 
profoundly impact tumor progression in vivo with its loss promoting increased tumor 
aggressiveness 55, 108, 195. 
 
Evasion of apoptosis by tumor cells enables them survive in an adverse 
microenvironment, and may powerfully cooperate with invasion/migration mechanisms 
to promote metastasis by allowing survival through the various steps of metastatic 
process 210. Loss of ARF has been linked to tumor invasiveness and metastasis in a mouse 
skin cancer model. Studies from our lab have shown that CtBP2 promotes the migration 
of cancer cells, and ARF can effectively inhibit CtBP2-mediated cancer cell migration 109. 
The mechanism by which CtBP regulates this function reflects the wide variety of genes 
regulated by them. Transcriptional regulation of the phosphatase PTEN by CtBPs seems 
to play an important role by activating the PI3-Kinase pathway and in turn, inducing 
cancer cell migration 109. Thus, selective pressure for ARF silencing or deletion in human 
epithelial cancers could due to p53-independent tumor cell apoptosis through CtBP 
degradation could also lead to the augmentation of the process of invasion and metastasis. 
Further understanding of role of CtBP in cell migration, invasion and EMT might also 
enable the development of targeted therapeutics.  
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p53-null and Arf-null mice develop highly penetrant lymphomas and sarcomas 
with mean latencies of 20 and 32 weeks respectively 25, 152. Analysis of Arf/p53-double 
null and Arf/Mdm2/p53-triple null mice revealed that Arf functions as tumor suppressor 
independent of p53 and Mdm2, especially during epithelial tumorigenesis, as there was 
an increased incidence of carcinomas in these animals. In an attempt to understand the 
biological significance of ARF/CtBP2 interaction in vivo, we have generated p19ArfL46D 
knock-in mice. Primary mouse embryonic fibroblasts (MEFs) were used to study the 
effects of abrogation of Arf/CtBP2 interaction on cell survival and migration. 
Homozygous L46D MEFs displayed an unexpected increased proliferation rate, 
proliferating at rates lower than Arf-null MEFs but higher than wildtype MEFs. The 
mechanism for this effect on proliferation rate is unclear as the increased proliferation 
rate of Arf-null MEFs is due to a reduction in the expression of p21Cip1, a p53 target gene, 
while, there was no significant difference in p16INK4a and p21Cip1 in L46D MEFs. 
However, the contribution of other pro-survival CtBP2 targets such as p15INK4b or other 
uncharacterized targets to the growth advantage of L46D MEFs cannot be ruled out. 
 
Although L46D MEFs continued grew at a higher proliferation rate than wildtype 
MEFs, they failed to undergo spontaneous immortalization, suggesting that the L46D 
mutation may not greatly affect the p53-dependent functions of ARF, such as 
spontaneous immortalization, in mouse primary embryonic fibroblasts. Interestingly, 
L46D/- hemizygous MEFs showed an increased tendency to undergo spontaneous 
immortalization compared to L46D/L46D homozygous MEFs. This clearly suggest that  
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Figure 5.1 Model for ARF regulation of CtBP2 functions 
Hypoxic conditions in cells enhance CtBP dimerization, NADH binding and an efficient 
transcriptional repression of target genes such as PTEN, INK4a, BH3-only genes 
contributing to tumor progression. When cancer cells retain ARF expression, ARF 
induces CtBP degradation, and reverses the CtBP-mediated repression of target genes 
resulting in robust tumor suppression.  
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This clearly suggest that both p53-dependent and p53-independent functions of Arf may 
exert additive effects to cause spontaneous immortalization. To rule out completely the 
possibility that the L46D mutation in p19Arf may contribute to the regulation of cell 
growth through p53, MEFs should be generated from L46D/p53-null mice, and compared 
their cell proliferation rate to that of each single homozygote background. Further, the 
tumor spectrum in L46D/p53-null mice would be worth investigating to determine the 
possibility of cross talk between the p53-depenedent and p53-independent functions of 
ARF.   
 
Unlike human ARF, p19Arf-induced CtBP2 degradation required an additional UV 
stress in mouse cells. There was no significant difference in the CtBP2 protein levels in 
L46D homozygote cells or Arf-null MEFs compared to that of wildtype. It is quite 
possible that these cells will require additional UV stress to undergo ARF-induced CtBP 
degradation to appreciate any changes in CtBP2 protein levels. Since, no known 
functions of ARF have been assigned to the CtBP-binding hydrophobic region of ARF, 
the possibility of other proteins interacting with this domain and their contributions to the 
observed phenotype in L46D cells cannot be ruled out completely. To address this 
hypothesis, generation of knock-in mice with mutation in CtBPs that disrupt their 
interaction with ARF, should be considered for future studies. One such candidate 
mutation in CtBP2 is the HipK2 phosphorylation site mutation S428A, which 
functionally abrogates ARF/CtBP2 degradation.  
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Genetic disruption of Arf in MEFs enhances cell migration as shown previously 
203. MEFs isolated from p19ArfL46D embryos showed increased cell migration compared to 
wildtype MEFs but not as robust as Arf-null MEFs. More interestingly, loss of one 
complete allele of Arf and L46D mutation in another allele (L46D/- hemizygous mice) 
demonstrated an even more robust migratory phenotype than that of L46D MEFs, 
confirming the contribution of both p53-dependent and p53-independent functions of Arf 
towards regulation of cell migration  109. 
 
Arf-null mice and p19ArfL46D knock-in mice are viable. Unlike Arf-null mice, 
L46D mice may not be susceptible to the typical and highly penetrant lymphomas and 
sarcomas as seen in Arf-null or Ink4a/Arf-null mice. These tumors arise due to a defect in 
p53-dependent apoptosis in tumor cells of these lineages 16. Quite possibly, L46D 
homozygote mice will develop more carcinomas with much delayed latency than Arf-null 
mice, as the L46D allele retains p53-dependent functions. In Arf-null mice, early onset of 
sarcomas and lymphomas is believed to mask susceptibility to more latent carcinomas, 
that are more frequently seen in Arf/p53 double-null or Arf/p53/Mdm2 triple-null mice 31. 
Thus, it will be critical to breed ArfL46D homozygous mice to a p53-null background to 
see if the tumor spectrum seen in p53-null animals is widened to the same degree to 
include more epithelial tumors as seen in Arf/p53 double-null animals.  
 
The tumor spectrum of L46D/- hemizygous mice and p53-null background would 
enable us to understand the contribution of the CtBP-binding hydrophobic region of 
123 
 
 
 
ARF, to p53-indpendent tumor suppressor function of Arf. If no additional tumors 
developed in the L46D and L46D/p53-null background, consideration should be given to 
induce epithelial tumors in specific tissues of these mice with mutagens such as DMBA 
for skin tumors, azoxymethane for intestinal tumors, or cross into tissue specific 
oncogene tumor models including melanoma, breast cancer or pancreatic cancer models 
211. However, the initial focus should be given to address the role of ARF/CtBP2 
interaction in intestinal tumors, as this interaction was characterized in human colon 
cancer cells and human colorectal adenocarcinomas tissue samples 68, 109.  To study the 
impact of the abrogation of ARF/CtBP interaction on the development of intestinal 
tumors, L46D mice should be crossed with min intestinal adenoma-prone mice followed 
by the comparison of tumor latency, number, size of tumors and survival of mice between 
the wildtype and L46D background.  
 
In conclusion, the data presented in this dissertation contributes to our 
understanding of a novel molecular mechanism governing the p53-independent tumor 
suppressor functions of ARF. In the past, p53-dependent pathways were exploited to 
develop effective therapeutics to treat cancer. However, p53 is mutated or inactivated in 
more than 50% of human cancers.  Thus, it is important to study and understand p53-
independent tumor suppressor pathways. The role of CtBP in modulating oncogenic 
outcomes through activation of migration/invasion/epithelial-mesenchymal transition and 
suppression of apoptosis raises the possibility that CtBPs may be useful anti-neoplastic 
drug targets. Further understanding of the cellular consequences of ARF/CtBP2 
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interaction will lead to increased ability in manipulating this pathway for therapeutic 
benefit in tumors that lack normal p53 function, which constitute the majority of human 
solid tumors.  
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This appendix contains research work and publications to which I have contributed, but 
that are not included in the main part of my dissertation 
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Appendix-I 
 
ARF may function as proteasome adapter via the S6a proteasome 
  
UV treatment of mouse cells resulted in proteasome dependent degradation of 
CtBP2 only when ARF was present, suggesting that UV-mediated degradation of CtBP 
required an intact ARF/CtBP interaction. Interestingly, there was no significant change in 
levels of ubiquitination of CtBP2 upon ARF overexpression (Figure A1.1A). ARF also 
induces sumoylation of its interacting proteins 157, CtBP1 has been shown to get 
sumoylated at S428 212. However, CtBP2 lacks the CtBP1 sumoylation consensus 
sequence (Fig A1.1B), thus, excluding the possibility of sumoylation playing role in 
ARF-induced degradation of CtBP2. ARF has been described as an interaction partner of 
the S6a subunit of the 19s proteasome 167. To determine whether ARF might act as an 
adaptor between ubiquitinated CtBP and the proteasome, the interaction of S6a and ARF 
was confirmed by CoIP 167. Lysates of U2OS cells expressing T7-hARF and cDNA for 
either the V5-tagged S5a or S6a subunit of the 19s proteasome, were immunoprecipitated 
with normal IgG, V5 or T7 antibodies. As reported previously 167, robust interaction 
between ARF and S6a was noted, as both proteins were found in the V5 and T7 IPs, but 
neither was seen in the control IPs (Figure A1.1C). Interestingly, another subunit of the 
19s regulatory particle, S5a, did not coIP with ARF when it was used as bait,  although it 
was observed in the T7-ARF IP  (Figure A1.1C) with lower stoichiometric relation than 
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S6a, suggesting that the ARF-S5a interaction was weaker and indirect, possibly as part of 
the larger 19s proteasome assembly being in complex with ARF.  
  
To pursue the idea that ARF may serve as a ‘receptor’ or proteasome adaptor for 
CtBP, its association with the proteasome complex has investigated. Lysates with intact 
proteasomes prepared from H1299 human lung cancer cells, which express endogenous 
ARF, were subjected to gel filtration chromatography. The fractions were analyzed for 
coelution of the S6a subunit, ARF and 20s proteasome subunits using anti-ARF, S6a and 
proteasome core subunit specific antibodies. Consistent with the in vitro binding assays 
(with the free forms S6a and ARF), both S6a and ARF coeluted with the 26s proteasome 
(Figure A1.1D). However, ARF did not coelute with the 20s proteasome suggesting that 
ARF interacts with only the 19s regulatory assembly that recruits it to the 26s complex. 
This preliminary evidence suggest that ARF may recruit ubiquitinated substrates such as 
CtBP, to the 26s proteasome for degradation through its interaction with S6a.    
  
  
128 
 
 
 
Figure A1.1 ARF may function as proteasome adapter via S6a subunit of 
proteasome.  
A. Effect of ARF on CtBP2 ubiquitination. Human colon cancer HCT116; p53-/- cells 
were transfected with CtBP2 and HA-ubiquitin, and after 16 hours of transfection cells 
were transduced with Ad-lacZ or Ad-ARF. Whole cell lysates were harvested and 
immunoprecipitated with anti-HA, followed by CtBP2 immunoblot. Ub-CtBP2 indicates 
the migration pattern of ubiquitinated CtBP2. B. CtBP1 has been reported to be 
sumoylated at S428; however CtBP2 lacks this sumoylation consensus sequence. C. ARF 
interacts with the S6a subunit of the 19s proteasome regulatory assembly. Human 
osteosarcoma, U2OS cells were cotransfected with T7-ARF expression construct along 
with either S5a-V5 or S6a-V5 expression plasmids. Whole cell lysates harvested after 36 
hours of transfection were immunoprecipitated with the control IgG, anti-V5 or anti-T7 
antibodies and followed by immunoblotting with anti-V5 or –T7 antibodies. D. ARF and 
the S6a subunit of the 19s proteasome coelute in gel filtration chromatography. Whole 
cell lysates were harvested from H1299 human lung carcinoma cells using low salt lysis 
buffer and applied to a Superose 6 Column after pre-purification over Heparin Sepharose 
column.  
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Appendix-II 
ARF/CtBP2 transcriptionally regulates PTEN tumor suppressor 
 
 CtBPs have been directly implicated in pro-oncogenic functions such as survival, 
hypoxia induced migration, and in turn, epithelial-mesenchymal transition 70, 105, 111. 
Studies from our lab reported that CtBPs activated upon metabolic stress, such as, 
hypoxia, repress epithelial and proapoptotic genes and can promote hypoxia-induced 
migration of cancer cells. Further, introduction of ARF during hypoxia effectively 
inhibited hypoxia-induced cell migration 109. Depletion of ARF or overexpression of 
CtBP2 in a p53-null human colon cancer cell line led to the activation of the PI3Kinase 
pathway and down regulation of PTEN expression 109.  PTEN was also found in a 
microarray analysis of CtBP repressed genes 72. The PTEN promoter contains five 
consensus-binding sites for basic Kruppel-like factor (BKLF) (Figure A2.1A). BKLF as a 
core repressor that can recruit CtBPs and other factors, and mediate transcriptional 
repression. Thus, the transcriptional regulation of PTEN expression by ARF/CtBP2, was 
explored. To assess the effects of CtBP2 depletion and ARF overexpression on PTEN 
expression quantitatively, PTEN mRNA levels were analyzed in HCT116; p53 -/- cells 
24 hrs after either depletion of CtBP2 using siRNA, or ARF overexpression by retroviral 
infection (Figure A2.1B).  Real-time PCR analysis confirmed that PTEN expression was 
increased upon either CtBP2 depletion (4.8-fold) or ARF overexpression (3.7 fold) in 
HCT116; p53-/- cells (Figure A2.1B). Similarly, the protein levels of PTEN were found 
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to be upregulated in CtBP2 siRNA treated cells as compared to control siRNA treated 
cells 109.  
 To determine whether the recruitment of CtBP by BKLF at the PTEN promoter 
could repress PTEN promoter activity, a 2.0 kb PTEN promoter luciferase reporter 
construct was transfected into U2OS cells with a BKLF, ARF, and CtBP2 expression 
vectors, as indicated. Either BKLF or CtBP2, alone, reduced the reporter activity by 40% 
(Figure A2.1C 1st and 3rd bar), however CtBP2/BKLF coexpressed further reduced the 
PTEN reporter activity by 20% (Figure A2.1C 2nd and 4th bar). Overexpression of ARF 
caused a reversal of CtBP2-mediated repression, which is consistent with the finding that 
ARF degrades CtBP2, and inhibits its repressor activity.  
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Figure A2.1 ARF/CtBP2 transcriptionally regulates PTEN tumor suppressor.  
A. RNA prepared from HCT116; p53−/− cells with either CtBP2 knockdown or ARF 
infection was  used to carry out quantitative real time PCR using PTEN and GAPDH 
specific primers. Graph represents GAPDH-normalized average fold change of PTEN in 
treated cells.  Error bars represent +/- 1 standard deviation (SD) B. Diagram of BKLF 
recognition elements in the PTEN promoter.  C. ARF antagonizes CtBP/BKLF 
repression of the PTEN promoter. PTEN-luciferase reporter was cotransfected with 
expression constructs for ARF, BKLF, or CtBP2 into U2OS cells along with a control 
reporter plasmid expressing Renilla luciferase (pRL-TK). Normalized firefly luciferase 
activity from three independent experiments was averaged, and error bars indicate +/- 1 
SD and with the p < 0.05.  
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